<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Pharm Res</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Pharmaceutical Research</journal-title></journal-title-group><issn pub-type="ppub">0724-8741</issn><issn pub-type="epub">1573-904X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12222261</article-id><article-id pub-id-type="pmcid-ver">PMC12222261.1</article-id><article-id pub-id-type="pmcaid">12222261</article-id><article-id pub-id-type="pmcaiid">12222261</article-id><article-id pub-id-type="pmid">40473892</article-id><article-id pub-id-type="doi">10.1007/s11095-025-03878-4</article-id><article-id pub-id-type="publisher-id">3878</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Finite Absorption Time Concept Guiding Model Informed Drug &amp; Generics Development in Clinical Pharmacology</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2375-0552</contrib-id><name name-style="western"><surname>Macheras</surname><given-names initials="P">Panos</given-names></name><address><email>macheras@pharm.uoa.gr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsekouras</surname><given-names initials="AA">Athanasios A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>S&#225;nchez-Herrero</surname><given-names initials="S">Sergio</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kosmidis</surname><given-names initials="K">Kosmas</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gnjpq42</institution-id><institution-id institution-id-type="GRID">grid.5216.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 0800</institution-id><institution>Faculty of Pharmacy, </institution><institution>National and Kapodistrian University of Athens, </institution></institution-wrap>Athens, Greece </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0576by029</institution-id><institution-id institution-id-type="GRID">grid.19843.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0393 5688</institution-id><institution>PharmaInformatics Unit, </institution><institution>ATHENA Research Center, </institution></institution-wrap>Athens, Greece </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gnjpq42</institution-id><institution-id institution-id-type="GRID">grid.5216.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 0800</institution-id><institution>Department of Chemistry, </institution><institution>National and Kapodistrian University of Athens, </institution></institution-wrap>Athens, Greece </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01f5wp925</institution-id><institution-id institution-id-type="GRID">grid.36083.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 6620</institution-id><institution>Department of Computer Science, </institution><institution>Multimedia and Telecommunication, Universitat Oberta de Catalunya, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04838xh83</institution-id><institution-id institution-id-type="GRID">grid.13622.34</institution-id><institution>Simulation Department, </institution><institution>Empresarios Agrupados Internacional S.A, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02j61yw88</institution-id><institution-id institution-id-type="GRID">grid.4793.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0945 7005</institution-id><institution>Division of Theoretical Physics, Physics Department, </institution><institution>Aristotle University of Thessaloniki, </institution></institution-wrap>54124 Thessaloniki, Greece </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>42</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">492120</issue-id><fpage>891</fpage><lpage>906</lpage><history><date date-type="received"><day>8</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-04 02:26:09.970"><day>04</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11095_2025_Article_3878.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To show the implications of the incorporation of the Finite Absorption Time (F.A.T.) concept in drug development plans and in generics development and assessment and to examine regulatory implications.</p></sec><sec><title>Methods</title><p id="Par2">Reexamining and reanalyzing published pharmacokinetic data using the pertinent models that are based on F.A.T.</p></sec><sec><title>Results</title><p id="Par3">Comparing absorption metrics, old and new ones, shows distinct advantages and better accuracy for those based on the F.A.T. concept.</p></sec><sec><title>Conclusion</title><p id="Par4">The proposed approaches can be applied successfully in all phases of drug/generics development and guide changes in their strategy and in the relevant regulatory framework.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bioequivalence</kwd><kwd>Finite absorption time</kwd><kwd>IVIVC</kwd><kwd>Oral drugs</kwd><kwd>Pharmacokinetics</kwd><kwd>Physiologically based finite time pharmacokinetic models</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Athens</institution></funding-source></award-group><open-access><p>Open access funding provided by HEAL-Link Greece.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Clinical pharmacology is inherently a translational discipline engaged in the experimental and observational study of the disposition and effects of drugs in humans. Until the 1960 s variability in drug response was always associated with the patient in accord with Sir William Osler&#8217;s variability principle which says &#8220;Variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no individuals react alike and behave alike under the abnormal conditions which we know as disease&#8221; [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In the early 1970 s, however, it was realized that a variable or poor response to a therapeutic agent may not have its origin in the patient; it may be due to a formulation defect in the drug product administered [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The introduction of the bioavailability concept by the U.S. Food and Drug Administration [<xref ref-type="bibr" rid="CR5">5</xref>] in 1977, was a logical consequence for the protection of public health. Since then, the intertwined emergence of bioavailability and clinical pharmacology lead to the incorporation of advanced quantitative methods into regulatory procedures, the so-called Model Informed Drug Development (MIDD) initiative, which modernize the development and regulation of drugs, as well as their use in the practice of medicine [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. Overall, MIDD approaches rely on pharmacokinetic, pharmacodynamic and pharmacometrics studies in all phases of drug development [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] as well as the individualization of drug therapy [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">In the field of oral drug absorption, Dost described in his first two pharmacokinetics books published in 1953 and 1968 [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] the blood drug concentration as a function of time assuming first-order absorption kinetics [<xref ref-type="bibr" rid="CR11">11</xref>], which implies that drug absorption runs for infinite time. However, the recent analysis of oral drug absorption based on the finite absorption time (F.A.T.) concept [<xref ref-type="bibr" rid="CR12">12</xref>] and the relevant physiologically based finite time pharmacokinetic (PBFTPK) models developed, provided meaningful and reliable estimates for the duration of drug absorption, <italic toggle="yes">&#964;</italic>, as well as for the corresponding drug input rate(s) [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. We also uncovered the real meaning of the fundamental parameters <italic toggle="yes">C</italic><sub>max</sub> and <inline-formula id="IEq1"><alternatives><tex-math id="d33e302">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e307"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> in the light of the physiologically sound F.A.T. concept [<xref ref-type="bibr" rid="CR14">14</xref>]. This realization coupled with the analytical power of PBFTPK models providing new parameters for oral drug absorption, leads to the emergence of a new world in all phases of drug and generics development. In this context, we propose i) to alter the strategy in the early phases and Phase I studies of drug development enriching the Phase I studies with an absolute bioavailability study, ii) to utilize PBFTPK models in the analysis of pharmacokinetic, pharmacodynamic, pharmacometric data in Phase II and III studies, iii) to change the strategy of generics development and iv) to apply model-dependent and model independent approaches for bioequivalence assessment based on the F.A.T. concept.</p></sec><sec id="Sec2"><title>Drug Development</title><sec id="Sec3"><title>Early Phases and Phase I Studies</title><p id="Par7">Upon completion of the preclinical phase, <italic toggle="yes">in silico</italic> approaches [<xref ref-type="bibr" rid="CR16">16</xref>], including physiologically based pharmacokinetic <bold>(</bold>PBPK) modeling, are frequently applied, which are followed by Phase I studies to find the optimal dose and assess safety (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). The PBPK models are used for predicting drug&#8217;s absorption, distribution, metabolism and excretion based on the physiological, physical, and chemical descriptions of the phenomena involved. For PBPK models focusing on gastrointestinal absorption, the preclinical data of the biopharmaceutical properties solubility, permeability and factors such as dose and drug particle size associated with drug dissolution are of extreme importance. In some cases, big pharmaceutical companies developing poorly soluble drugs, e.g., anticancer, like to know the extent of drug&#8217;s absorption prior to Phase I studies and the huge investment and perform laborious microdosing or phase zero studies [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, the current scenario of early phases and Phase I studies is depicted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A in chronological order. In the PBPK modelling studies first-order kinetics is being used since the absorption rate constant <italic toggle="yes">k</italic><sub>a</sub> is linked with the effective permeability <italic toggle="yes">P</italic><sub>eff</sub> and radius <italic toggle="yes">R</italic> of the gastrointestinal lumen, namely, <italic toggle="yes">k</italic><sub>a</sub>&#8201;= 2 <italic toggle="yes">P</italic><sub>eff</sub>/<italic toggle="yes">R</italic>, while finite transit times are allocated in the drug movement among the compartments of the gastrointestinal tract [<xref ref-type="bibr" rid="CR16">16</xref>]. Thus, the predicted % absorbed <italic toggle="yes">versus</italic> time curves of these studies have a mono-exponential pattern (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). This plot has its roots in the Wagner-Nelson and Loo-Riegelman papers of the 1960 s [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>], which have been transformed and used today in deconvolution software. However, the equations describing the percent of drug absorbed as a function of time quoted in refs [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>] were modified in Ref [<xref ref-type="bibr" rid="CR27">27</xref>] in accord with the F.A.T. concept; we have also proved that this plot is either linear (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B) or multilinear (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C, D), if more than one linear drug input rates are encountered.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>(<bold>A</bold>) Currently used studies in early phase of drug development in chronological order. (<bold>B</bold>) Proposed additional F.A.T. driven Phase I studies followed by enriched PBPK modeling work. (<bold>C</bold>) Future developments: Towards a predictive experimental device, the <italic toggle="yes">&#8220;3D absorption map&#8221;</italic> era and the predictive absorption models based on molecular structure using machine learning techniques.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>A paradigm shift in oral drug absorption. (<bold>A</bold>) Currently, the percent absorbed A% <italic toggle="yes">versus</italic> time curves follow a mono-exponential pattern based on the prevailing hypothesis of first-order absorption kinetics. (<bold>B</bold>) Linear percent absorbed <italic toggle="yes">versus</italic> time plot in accord with the F.A.T. concept assuming one input stage [<xref ref-type="bibr" rid="CR27">27</xref>]. (<bold>C</bold>) Percent absorbed <italic toggle="yes">versus</italic> time curve for almotriptan with two linear absorption segments (redrawn from Fig. <xref rid="Fig8" ref-type="fig">8</xref> in [<xref ref-type="bibr" rid="CR15">15</xref>] using Eq. <xref rid="Equ6" ref-type="disp-formula">6</xref> from Ref. [<xref ref-type="bibr" rid="CR27">27</xref>]). (<bold>D</bold>) Percent absorbed <italic toggle="yes">versus</italic> time curve for cyclosporine reference product under fed conditions exhibiting three linear absorption segments (data replotted from Fig. <xref rid="Fig9" ref-type="fig">9</xref>D in [<xref ref-type="bibr" rid="CR15">15</xref>] using Eq. <xref rid="Equ6" ref-type="disp-formula">6</xref> from Ref. [<xref ref-type="bibr" rid="CR27">27</xref>]).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig2_HTML.jpg"/></fig></p><p id="Par8">The advances in the understanding of gastrointestinal absorption based on the F.A.T. concept and the use of PBFTPK models so far point to the enriched scenario for Phase I studies depicted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B. According to this scheme, the classical Phase I studies to find the optimal dose and assess safety are supplemented with an oral absolute bioavailability study applying for example blood sampling and urine collection. From the analysis of blood concentration, time data, the characteristics of drug absorption are estimated using the PBFTPK models, namely, i) the number of absorption stages, ii) the corresponding drug input rates and iii) the duration of each stage <italic toggle="yes">&#964;</italic><sub><italic toggle="yes">i</italic>,</sub> as well as the total duration of absorption, <italic toggle="yes">&#964;</italic> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). These data will be useful for simulating dosage regimen designs for therapeutic purposes. Additionally, useful conclusions can be drawn for the formulation development plan. For example, the analysis of a typical BCS Class II drug carbamazepine [<xref ref-type="bibr" rid="CR28">28</xref>] reveals a long duration of absorption (<italic toggle="yes">&#964;</italic>&#8201;&gt; 16 h), which rules out the development of a sustained release formulation, a desirable trait due to its chronic use. The analysis of the absolute bioavailability study can be performed using Eqs. <xref rid="Equ1" ref-type="disp-formula">1</xref> and <xref rid="Equ2" ref-type="disp-formula">2</xref> (see the derivation of Eq.&#160;<xref rid="Equ1" ref-type="disp-formula">1</xref> in the appendix).<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e519">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{\tau }^{\infty }=\frac{FD-{Q}_{el}(\tau )}{CL}$$\end{document}</tex-math><mml:math id="d33e525" display="block"><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mi>D</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">el</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ1.gif"/></alternatives></disp-formula></p><p id="Par9">Dividing Eq.&#160;<xref rid="Equ1" ref-type="disp-formula">1</xref> with the fundamental equation <inline-formula id="IEq2"><alternatives><tex-math id="d33e561">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }=FD/CL$$\end{document}</tex-math><mml:math id="d33e566"><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mi>F</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq2.gif"/></alternatives></inline-formula>, one can derive the following expression for the bioavailable fraction, <italic toggle="yes">F</italic>:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e588">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$F=\frac{{Q}_{\text{el}}(\tau )}{D}{\left(1-\frac{{\left[AUC\right]}_{\tau }^{\infty }}{{\left[AUC\right]}_{0}^{\infty }}\right)}^{-1}$$\end{document}</tex-math><mml:math id="d33e594" display="block"><mml:mrow><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>D</mml:mi></mml:mfrac><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ2.gif"/></alternatives></disp-formula>where <italic toggle="yes">D</italic> is the drug dose, <italic toggle="yes">Q</italic><sub>el</sub>(<italic toggle="yes">&#964;</italic>) is the amount eliminated up to time <italic toggle="yes">&#964;</italic>, and <italic toggle="yes">CL</italic> is the drug clearance. We present a relevant example using the alendronate blood and urine data reported in the literature [<xref ref-type="bibr" rid="CR29">29</xref>]. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> shows the fitting of the PBFTPK model [<xref ref-type="bibr" rid="CR15">15</xref>] with one input stage assuming one compartment model disposition to drug blood data. An estimate for <italic toggle="yes">Q</italic><sub>el</sub>(<italic toggle="yes">&#964;</italic>) equal to 175 &#956;g was derived from the urine data reported in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B of [<xref ref-type="bibr" rid="CR29">29</xref>] using interpolation at time <italic toggle="yes">&#964;</italic>&#8201;= 0.86 h. The estimate for <italic toggle="yes">F</italic> using Eq.&#160;<xref rid="Equ2" ref-type="disp-formula">2</xref> was found equal to 175 &#956;g/70 mg [1-(83&#8211;13.8)/83]<sup>&#8722;1</sup>&#8201;= 1.5%, while the plateau value of the urine excretion 727 &#956;g (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B in [<xref ref-type="bibr" rid="CR29">29</xref>]) divided by the dose 70 mg gives an estimate 1.03%; these estimates for <italic toggle="yes">F</italic> are very close to the literature value, 0.7% [<xref ref-type="bibr" rid="CR30">30</xref>]. In this example, the estimation of <italic toggle="yes">Q</italic><sub>el</sub>(<italic toggle="yes">&#964;</italic>) was rather simple since alendronate is not metabolized and is eliminated via renal excretion [<xref ref-type="bibr" rid="CR30">30</xref>]. For drugs metabolized, however, measurements for the eliminated metabolite(s) are required for the correct estimation of <italic toggle="yes">Q</italic><sub>el</sub>(<italic toggle="yes">&#964;</italic>)<italic toggle="yes">.</italic>
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Best fit results of the PBFTPK model [<xref ref-type="bibr" rid="CR15">15</xref>] with one input stage assuming one-compartment model disposition to alendronate experimental blood data [<xref ref-type="bibr" rid="CR29">29</xref>]. The symbol &#9650; denotes the end of the absorption processes. <italic toggle="yes">V</italic><sub><italic toggle="yes">d</italic></sub> is the volume of drug distribution and <italic toggle="yes">k</italic><sub><italic toggle="yes">el</italic></sub> is the elimination rate constant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig3_HTML.jpg"/></fig></p><p id="Par10">Another useful approach for the estimation of absolute bioavailability relies on the so called &#8220;Semi simultaneous approach&#8221; [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>], which can be easily adapted in the realm of F.A.T. concept by administering the intravenous bolus dose beyond the end of the absorption process, <italic toggle="yes">&#964;</italic>. We re-analyzed the LiCl rat data in [<xref ref-type="bibr" rid="CR32">32</xref>] by fitting the PBFTPK model with one input stage and two compartment disposition to the entire set of intraperitoneal-intravenous data, adjusting the duration of absorption for the intraperitonial administration in accord with the sampling design, while the duration of the intravenous administration was set equal to 36 s. The estimated absolute bioavailability of the intraperitonially administered formulation based on &#8220;the concentration maxima&#8221; of the two administrations was found equal to one very close to the estimate derived from the conventional methodology based on the comparison of areas under the curve [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par11">Overall, the estimates for <italic toggle="yes">&#964;</italic>, number-duration-magnitude of drug input rates, <italic toggle="yes">F</italic> and <italic toggle="yes">V</italic><sub>d</sub> values derived from the absolute bioavailability study will formulate the basics for drug development. These results show that the microdosing studies quoted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A can be replaced by the bioavailability study as part of the Phase I studies (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). Although investigators during Phase I studies are looking at the effects of the medication on about 20 to 80 healthy volunteers to figure out the highest dose humans can take without serious side effects, the performance of the absolute bioavailability study will allow this consideration to be based on the actual bioavailable dose. Hence, Phase I studies for oral drugs can be renamed &#8220;<italic toggle="yes">Phase I: First dose in man studies/Absolute bioavailability assessment</italic>&#8221; since the estimate for <italic toggle="yes">F</italic> will be in the heart of all phases of drug development<italic toggle="yes">.</italic> In other words, the strategy of drug development will change as shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B. According to the scenario depicted in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B, the estimates derived from this analysis will be used in an enriched PBPK modeling exercise focusing on the optimization of formulation in terms of the dose and particle size of drug. Thus, the estimate for <italic toggle="yes">&#964;</italic> can be applied to finite time dissolution functions, e.g., Noyes-Whitney and the Weibull equations [<xref ref-type="bibr" rid="CR34">34</xref>] used in the enriched PBPK work (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B), for studying the effect of drug&#8217;s particle size and dose variation on the predicted blood concentration, time profile. Besides, the estimate for <italic toggle="yes">&#964;</italic> will guide the enriched PBPK modeling work; for example, if <italic toggle="yes">&#964;</italic> is less than 5&#160;h, drug absorption takes place in the small intestine and colon absorption is ruled out. It should also be mentioned that the estimate for the volume of drug&#8217;s distribution (derived from the <italic toggle="yes">FD/V</italic><sub>d</sub> estimate of the PBFTPK model fitting and the estimate for <italic toggle="yes">F</italic> from the absolute bioavailability study) allows its use in the PBPK modeling work and the expression of drug blood levels in real, clinically relevant units. It can be anticipated that the use of PBFTPK models for the analysis of pharmacokinetic data coupled with the methods for the estimation of <italic toggle="yes">F</italic> will be applied to many drugs. Plausibly, this will progressively lead to the creation of a <italic toggle="yes">&#8220;3D absorption map&#8221;</italic> with the <italic toggle="yes">xy</italic> plane corresponding to the input rate and the elimination rate constant, which drives the elimination rate, while the <italic toggle="yes">z</italic>-axis will represent the <italic toggle="yes">F</italic> estimates (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C). Plausibly, the <italic toggle="yes">&#8220;3D absorption map&#8221;</italic> will be used as an advanced biopharmaceutic-pharmacokinetic system, e.g., biowaivers are in the region <italic toggle="yes">F</italic>&#8201;&gt; 0.90. Consecutively, this advancement will ultimately lead to <italic toggle="yes">in silico</italic> predictive absorption models since the input rate corresponds to the estimate of the ratio (<italic toggle="yes">FD</italic>/<italic toggle="yes">V</italic><sub>d</sub>)/<italic toggle="yes">&#964;</italic> while the elimination rate constant, <italic toggle="yes">k</italic><sub>el</sub> controls the elimination of drug. All parameters are strongly associated with drugs&#8217; molecular descriptors, physicochemical and biopharmaceutical properties. In other words, the strategy of development in the early phases for the estimation of absolute bioavailability will move progressively to &#8220;<italic toggle="yes">in silico</italic>&#8221; approaches utilizing machine learning techniques too (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C).</p><p id="Par12">The emergence of absolute bioavailability estimation with minimal intravenous sampling mentioned above will result in the reduction of intravenous administrations during drug development. In parallel, the development of oral drugs will be propelled and their clinical use will be substantiated from pharmacokinetic, pharmacodynamic studies centered around the estimated bioavailable dose. Thus, these advances can find favorable ground in anticancer chemotherapy, whereas the intravenous-to-oral switch has been under discussion for several years [<xref ref-type="bibr" rid="CR35">35</xref>]. This is also in line with the current tendency for deintensification in cancer care [<xref ref-type="bibr" rid="CR36">36</xref>] since oral formulations have lower bioavailability than the intravenous solutions. However, the lower bioavailability of the oral formulations may result in more frequent oral administration. Under these circumstances, the use of anticancer-milk oral formulations with enhanced bioavailability properties can be considered [<xref ref-type="bibr" rid="CR37">37</xref>]. It is advisable therefore, FDA to grant GRAS (Generally Regarded As Safe) status for the use of milk in anticancer and paediatric formulations considering the risk/benefit ratio and the fact that milk is or can be a daily ritual for the oncology patient. According to a recent study [<xref ref-type="bibr" rid="CR38">38</xref>], WHO has granted GRAS status to milk. Anticancer chemotherapy based on oral drug administration will certainly improve the life of oncology patients avoiding the hospitalization for the intravenous drug administration. Such a development will underscore the rise of &#8220;greener oncology therapy&#8221;.</p></sec><sec id="Sec4"><title>Phases II and III</title><p id="Par13">The vast majority of published pharmacokinetic, pharmacodynamic and pharmacometrics studies of Phases II and III dealing with oral drug absorption rely on first-order absorption models. In all these studies the fallacious first-order absorption rate constant governs and quantifies the rate of drug absorption. The first-order kinetic concept is being used arbitrarily in many drugs kinetic processes in the body; we quote here several examples. A first-order rate constant equal to 21 h<sup>&#8722;1</sup> is being used to model bile secretion [<xref ref-type="bibr" rid="CR39">39</xref>]; this magnitude implies a process which is 90% completed in only 6.5 min indicating that a zero-order consideration would be more physiologically relevant. Besides, when complex absorption profiles are encountered and first-order absorption kinetic models fail, stochastic approaches based on the inverse Gaussian function are employed [<xref ref-type="bibr" rid="CR40">40</xref>]. We have shown that the PBFTPK models capture the dynamics of the complex absorption phenomena and describe the drug input rates and the duration of the input stages based on meaningful parameters [<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, the frequently used gastro-intestinal transit time model [<xref ref-type="bibr" rid="CR41">41</xref>] utilizes five first-order rate constants (two in series for the drug transit and three in parallel for the drug uptake) and proved superior to the classical first-order model with a lag time. Although the fitting results can be superior, the physical meaning of the five absorption rate constants is questionable due to the finite character of both drug transit and absorption processes. Also, in the field of interspecies scaling and paediatric scaling, the inverse time units of the absorption rate constant do not allow a scaling exercise. In contrast, the physiologically based meaningful input parameters of the PBFTPK models if coupled with nonlinear mixed effect modeling will allow the scaling between adult and children or species oral data. Finally<italic toggle="yes">,</italic> we briefly touch the so-called flip flop kinetics, which is used in pharmacokinetics and pharmacometrics [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] under the assumption of lower value for the absorption rate constant compared to the elimination rate constant. Since this assumption is not valid under the prism of the F.A.T. concept, we present an example [<xref ref-type="bibr" rid="CR44">44</xref>] of a successful PBFTPK model fitting (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A) to doxycycline data [<xref ref-type="bibr" rid="CR45">45</xref>]. We also interpreted [<xref ref-type="bibr" rid="CR44">44</xref>] the concentration time profile of intramuscularly administered methylprednisolone acetate, which is a non-hydrosoluble pro-drug of methylprednisolone [<xref ref-type="bibr" rid="CR46">46</xref>], Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B, using fractal kinetics [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref>] assuming a time dependent coefficient (<inline-formula id="IEq3"><alternatives><tex-math id="d33e940">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k{t}^{-\lambda })$$\end{document}</tex-math><mml:math id="d33e945"><mml:mrow><mml:mi>k</mml:mi><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>&#955;</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq3.gif"/></alternatives></inline-formula> driving the input rate using the ODE, <inline-formula id="IEq4"><alternatives><tex-math id="d33e960">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{dC}{dt}=k{t}^{-\lambda }-{k}_{\text{el}}C$$\end{document}</tex-math><mml:math id="d33e965"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">dC</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>&#955;</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>C</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq4.gif"/></alternatives></inline-formula>. Both sets of data in [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] have been described with flip flop kinetics; our results invalidate this working hypothesis.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>(<bold>A</bold>) PBFTPK model nonlinear fitting [<xref ref-type="bibr" rid="CR13">13</xref>] with one input stage and two-compartment model disposition to doxycycline data [<xref ref-type="bibr" rid="CR45">45</xref>]. The symbol &#9650; denotes the end of the absorption process. (<bold>B</bold>) Fitting using a custom code written in Wolfram Language (Mathematica version 14.2) to methylprednisolone data [<xref ref-type="bibr" rid="CR46">46</xref>] after the intramuscular administration of methylprednisolone acetate, which is a pro-drug of methylprednisolone; the equation <inline-formula id="IEq5"><alternatives><tex-math id="d33e1017">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C\left(t\right)={e}^{{-k}_{\text{el}}t}{t}^{-\lambda }\left({n}_{0}{t}^{\lambda }-kt{E}_{1}\left(\lambda , -{k}_{\text{el}}t\right)\right)$$\end{document}</tex-math><mml:math id="d33e1022"><mml:mrow><mml:mi>C</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>-</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mtext>el</mml:mtext></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>&#955;</mml:mi></mml:mrow></mml:msup><mml:mfenced close=")" open="("><mml:msub><mml:mi>n</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mi>&#955;</mml:mi></mml:msup><mml:mo>-</mml:mo><mml:mi>k</mml:mi><mml:mi>t</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mi>&#955;</mml:mi><mml:mo>,</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>t</mml:mi></mml:mfenced></mml:mfenced></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq5.gif"/></alternatives></inline-formula> where <italic toggle="yes">E</italic><sub>1</sub>(<italic toggle="yes">&#955;</italic>,<italic toggle="yes">x</italic>) is the Exponential Integral function, which is the analytical solution of the ODE: <inline-formula id="IEq6"><alternatives><tex-math id="d33e1078">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{dC}{dt}=k{t}^{-\lambda }-{\text{k}}_{\text{el}}C$$\end{document}</tex-math><mml:math id="d33e1083"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">dC</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mi>&#955;</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msub><mml:mtext>k</mml:mtext><mml:mtext>el</mml:mtext></mml:msub><mml:mi>C</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq6.gif"/></alternatives></inline-formula> was used. Best fitting results, <italic toggle="yes">k</italic>&#8201;= 14.36 ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;0.56</sup>, <italic toggle="yes">&#955;</italic>&#8201;= 0.44, <italic toggle="yes">k</italic><sub>el</sub>&#8201;= 0.179 h<sup>&#8722;1</sup> and correlation coefficient, <italic toggle="yes">R</italic>.<sup>2</sup>&#8201;= 0.958.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig4_HTML.jpg"/></fig></p><p id="Par14">Population analyses are an integral part of Phases II and III studies. Consequently, another important area of the PBFTPK models&#8217; application is their use as structural models in population analysis studies. As mentioned above, the physiologically sound meaning of the parameters of the PBFTPK models will allow their scaling in interspecies and peadiatric pharmacokinetic population studies, which is not possible today because of the first-order nature of the absorption rate constant. We present preliminary results of a population PBFTPK model of abacavir in infants, toddlers and children with PhysPK&#174; based on Zhao <italic toggle="yes">et al.</italic> data [<xref ref-type="bibr" rid="CR50">50</xref>]. Abacavir concentration data from clinical studies in human immunodeficiency virus-infected children (<italic toggle="yes">n</italic>&#8201;= 69) were used for model building based on the two-compartment PBFTPK model. Preliminary results of this first application of PBFTPK models to population analysis were obtained. From abacavir studies, data was obtained from once daily dosage regimen 16 mg kg<sup>&#8722;1</sup>. A population pharmacokinetic analysis was performed using a one input stage PBFTPK two-compartment model [<xref ref-type="bibr" rid="CR15">15</xref>] with nonlinear mixed effects modelling with PhysPK&#174;. For this preliminary model no covariance was taken into account. The preliminary results of population pharmacokinetic parameters of abacavir are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Population Pharmacokinetic Parameters of Abacavir</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Estimate</th><th align="left" colspan="1" rowspan="1">Relative standard error (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">FD</italic>/<italic toggle="yes">V</italic><sub>d</sub> (mg/L)</td><td align="left" colspan="1" rowspan="1">333</td><td align="left" colspan="1" rowspan="1">43.6</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">&#964;</italic> (h)</td><td align="left" colspan="1" rowspan="1">1.74</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">Systemic clearance, <italic toggle="yes">CL</italic> (L h<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">22.1</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">Central volume of distribution, <italic toggle="yes">V</italic><sub>c</sub> (L)</td><td align="left" colspan="1" rowspan="1">24.68</td><td align="left" colspan="1" rowspan="1">3.29</td></tr><tr><td align="left" colspan="1" rowspan="1">Peripheral volume of distribution, <italic toggle="yes">V</italic><sub>p</sub> (L)</td><td align="left" colspan="1" rowspan="1">25.67</td><td align="left" colspan="1" rowspan="1">Fixed</td></tr><tr><td align="left" colspan="1" rowspan="1">Intercompartment clearance, <italic toggle="yes">Q</italic> (L h<sup>&#8211;1</sup>)</td><td align="left" colspan="1" rowspan="1">2.8</td><td align="left" colspan="1" rowspan="1">Fixed</td></tr></tbody></table></table-wrap></p><p id="Par15">The visual predictive check (VPC) in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref> of the final model, including all patients, showed that the observed concentrations did not align well with the predicted values, suggesting a need for model improvement. The inadequate fit might be attributed to fixing certain parameters, such as <italic toggle="yes">Q</italic> and <italic toggle="yes">V</italic><sub>p</sub>, instead of estimating them, and to the need for exploring alternative PBFTPK models. Additionally, subpopulation-specific VPCs (infants, toddlers, and children) and dosing regimens (once <italic toggle="yes">vs.</italic> twice daily) may provide further insights into model refinement. The NPDE distribution and histogram in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref> indicated deviations from the expected normal distribution of prediction errors, and trends observed in the NPDE diagnostic plots against time or predicted concentrations suggest that the model needs further adjustment.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Visual predictive check in children&#8217;s following once daily dosing regimen; observed data are plotted using a circle. The dashed lines represent the 5th and 95th percentiles of simulated data (<italic toggle="yes">n</italic>&#8201;= 1000). The continuous lines represent the 50<sup>th</sup> percentile of simulated data (<italic toggle="yes">n</italic>&#8201;= 1000).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig5_HTML.jpg"/></fig><fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Normalized prediction distribution errors (NPDE) analysis. (<bold>A</bold>) NPDE <italic toggle="yes">vs.</italic> time. (<bold>B</bold>) NPDE <italic toggle="yes">vs.</italic> population prediction concentrations (PRED). (<bold>C</bold>) Histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution overlaid. (<bold>D</bold>) QQ-plot of the distribution of the NPDE <italic toggle="yes">vs.</italic> the theoretical normal distribution.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec5"><title>Implications for the Development and Assessment of Generics</title><sec id="Sec6"><title>Generics Development</title><p id="Par16">The development of generics mostly relies on drug dissolution studies and the relevant <italic toggle="yes">in vitro</italic>
<italic toggle="yes">in vivo</italic> correlations (IVIVC) [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Almost twenty years ago we published [<xref ref-type="bibr" rid="CR53">53</xref>] a highly cited review on drug dissolution focusing &#8220;on the realization of a relationship between dissolution and bioavailability, which initiated the drug related interest in dissolution, and progressing to the present applications of dissolution studies, with both their scientific and regulatory aspects&#8221;. The concluding remark of this work [<xref ref-type="bibr" rid="CR53">53</xref>] was &#8220;The experience gained so far indicates that the design of a unique dissolution test to be used reliably as a prognostic tool of oral drug absorption will not appear in the near future.&#8221; Unfortunately, this conclusion is verified today despite the tremendous number of studies towards a formulation predictive dissolution testing to advance oral drug product development in the ensuing years [<xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR56">56</xref>]. Although the driving force behind these studies is the need to develop a predictive dissolution method that can be applied by pharmaceutical drug companies to facilitate marketing access for generic and novel drug products, the number of successful level A <italic toggle="yes">in vitro</italic>
<italic toggle="yes">in vivo</italic> correlations (IVIVC) [<xref ref-type="bibr" rid="CR57">57</xref>] is very limited.</p><p id="Par17">We argue below that one of the most important reasons for the failed IVIVC is associated with the &#8220;taken for granted&#8221; unphysical assumption of first order drug absorption which is present in all relevant portions of the guideline [<xref ref-type="bibr" rid="CR57">57</xref>] describing the calculation of the fraction of drug absorbed as a function of time. e.g., i) &#8220;A Level A correlation is usually estimated by a two-stage procedure: deconvolution followed by comparison of the fraction of drug absorbed to the fraction of drug dissolved&#8221;; ii) &#8220;In a linear correlation, the <italic toggle="yes">in vitro</italic> dissolution and <italic toggle="yes">in vivo</italic> input curves may be directly superimposable or may be made to be superimposable by the use of a scaling factor&#8221;; iii) &#8220;One alternative is based on a convolution procedure that models the relationship between <italic toggle="yes">in vitro</italic> dissolution and plasma concentration in a single step&#8221;; iv) &#8220;estimate the <italic toggle="yes">in vivo</italic> absorption or dissolution time course using an appropriate deconvolution technique for each formulation and subject (e.g., Wagner-Nelson, numerical deconvolution)&#8221;. The convolution, deconvolution terms in the guideline [<xref ref-type="bibr" rid="CR57">57</xref>] are in most cases computerized synonyms of the Wagner-Nelson [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and Loo-Riegelman [<xref ref-type="bibr" rid="CR26">26</xref>] techniques. Besides, the superimposable term above for the <italic toggle="yes">in vitro</italic> drug dissolution and <italic toggle="yes">in vivo</italic> input curve also implies first-order kinetics since dissolution is described by exponential functions based on first-order kinetic assumptions. However, the collapse of the first-order drug absorption hypothesis [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>], the modification of Wagner-Nelson [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and Loo-Riegelman [<xref ref-type="bibr" rid="CR26">26</xref>] equations in [<xref ref-type="bibr" rid="CR27">27</xref>] resulted in a paradigm shift in oral drug absorption, namely, the percent absorbed <italic toggle="yes">versus</italic> time curves are either bilinear or multilinear, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. These advances were further coupled with the physiologically sound finite dissolution time (F.D.T.) concept and resulted in the revision of IVIVC [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par18">All the above call for a change in the strategy of generics development based on the following steps. The first step consists of analysis of the reference <italic toggle="yes">in vivo</italic> data using the PBFTPK models. This will provide the detailed characteristics of the drug&#8217;s absorption, i.e., number, duration, input rate for each stage of drug absorption as well as the percent absorbed <italic toggle="yes">versus</italic> time curve of the reference formulation. Useful information will be extracted from this analysis in terms of the F.D.T. considering the F.A.T. estimate derived from the fitting of PBFTPK models to the experimental data of the reference formulation as described in [<xref ref-type="bibr" rid="CR28">28</xref>]. This will be followed by <italic toggle="yes">in vitro</italic> dissolution studies of the reference formulation in a flow through system, e.g., USP apparatus 4 using official dissolution media. This system ensures sink conditions which are in line with the sink conditions prevailing in the absorption of drugs from the gastrointestinal tract [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Ideally, the drug measurements will result in a linear percent <italic toggle="yes">in vitro</italic> dissolved <italic toggle="yes">versus</italic> time curve. The next step relies on the analysis of % absorbed <italic toggle="yes">versus</italic> % dissolved plot and the quest for IVIVC and/or the scaling factor and/or the ratio of the slopes of the <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> lines for the reference formulation. Finally, the pharmaceutical scientist runs dissolution experiments for the generic formulation(s) under development using the experimental conditions adhering to the best IVIVC established in the previous step using the reference formulation. In summary, the steps of the new strategy for the development of generics are as follows.<list list-type="order"><list-item><p id="Par19">Analysis of the <italic toggle="yes">in vivo</italic> reference formulation data using the PBFTPK models [<xref ref-type="bibr" rid="CR15">15</xref>]</p></list-item><list-item><p id="Par20">Construction of the percent absorbed <italic toggle="yes">versus</italic> time plot for the reference formulation [<xref ref-type="bibr" rid="CR27">27</xref>]</p></list-item><list-item><p id="Par21"><italic toggle="yes">In vitro</italic> dissolution studies of the reference formulation in a flow through system ensuring sink conditions</p></list-item><list-item><p id="Par22">Correlation based on % absorbed and % dissolved data of the reference formulation considering the F.A.T. and F.D.T. time constraints [<xref ref-type="bibr" rid="CR28">28</xref>]</p></list-item><list-item><p id="Par23">Dissolution experiments for the generic formulation based on the previous step best results</p></list-item></list></p><p id="Par24">In the spirit of the above plan, we analyze two studies [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] dealing with IVIVC to demonstrate the utility of the PBFTPK modelling (step 1) for the elucidation of mesalazine and efodipine absorption processes as well as the proper construction of the percent absorbed <italic toggle="yes">versus</italic> time plot (step 2).</p><p id="Par25">We analyzed upon digitisation, using PBFTPK models [<xref ref-type="bibr" rid="CR15">15</xref>], the bioequivalence data of mesalazine [<xref ref-type="bibr" rid="CR59">59</xref>] colon targeting tablets of a generic development product (test formulation, TF; mesalazine 400 mg tablet) and the original product (reference formulation, RF; Asacol&#174; 400 mg tablet) [<xref ref-type="bibr" rid="CR59">59</xref>]. The best fitting results using the PBFTPK models [<xref ref-type="bibr" rid="CR15">15</xref>] with one-compartment disposition for all formulations examined presented in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref> show the complexity of mesalazine absorption for the three administrations, i.e., 3, 6 and 12 tablets along with the duration of each absorption stage and the corresponding input rates. In Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref> we also present the percent absorbed <italic toggle="yes">versus</italic> time plots of multilinear character indicating the end of the absorption process, which ranges from 13.6 to 38.6 h verifying the colon targeting design of the tablets. The fitting results based on the analysis of the same data using first-order absorption models were inferior, while the profiles of the percent absorbed <italic toggle="yes">versus</italic> time plots were exponential. Overall, the dissolution data based on the flow through apparatus reported in [<xref ref-type="bibr" rid="CR59">59</xref>] cannot capture the dynamics of the complex mesalazine absorption behaviour shown in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>. Besides, the IVIVC developed in [<xref ref-type="bibr" rid="CR59">59</xref>] rely on the percent absorbed <italic toggle="yes">versus</italic> time plots derived from the deconvolution method used, which calculates the <italic toggle="yes">in vivo</italic> absorption rate without a time constraint based on the F.A.T. concept and the multiple zero-order absorption stages of the PBFTPK models. In view of the present findings the validity of the IVIVC developed in [<xref ref-type="bibr" rid="CR59">59</xref>] is questionable.<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Best fitting results of PBFTPK models to mesalazine data [<xref ref-type="bibr" rid="CR59">59</xref>]; each plot is followed by the corresponding percent absorbed <italic toggle="yes">versus</italic> time curve calculated using Eq.&#160;<xref rid="Equ2" ref-type="disp-formula">2</xref> from Ref. [<xref ref-type="bibr" rid="CR27">27</xref>]. The meaning of symbols can be found in [<xref ref-type="bibr" rid="CR59">59</xref>]. <italic toggle="yes">R</italic><sub>1</sub>, <italic toggle="yes">R</italic><sub>2</sub>, <italic toggle="yes">R</italic><sub>3</sub>, <italic toggle="yes">R</italic><sub>4</sub> denote rate of input at each input stage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1596" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig7a_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1597" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig7b_HTML.jpg"/></fig></p><p id="Par26">We also analyzed the three sets of the <italic toggle="yes">in vivo</italic> data of efodipine hydrochloride [<xref ref-type="bibr" rid="CR60">60</xref>] using PBFTPK models. Figure&#160;<xref rid="Fig8" ref-type="fig">8</xref> shows the best fitting results for the three formulations examined using a one-compartment disposition model as well as the corresponding percent absorbed <italic toggle="yes">versus</italic> time plots. Only the crude drug exhibited two absorption stages with a total absorption duration 6.8 h indicating that efodipine (EFH) is absorbed in the small intestine with a rate of 106 ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;1</sup> for 2&#160;h, while the second absorption stage with a rate of 70 ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;1</sup> lasts 4.5 h implying absorption from the colon too. On the contrary, EFH is absorbed from both dispersion formulations 1:1 and 1:3:1 in the small intestine following constant rates 175 ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;1</sup> for 42 min and 704 ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;1</sup> for 3.3 h, respectively. The dissolution EFH profiles of both dispersion formulations 1:1 and 1:3:1 reported in [<xref ref-type="bibr" rid="CR60">60</xref>] are nonlinear even though a flow through dissolution device was utilized. Accordingly, IVIVC cannot be explored as suggested in the &#8220;IVIVC revised&#8221; article [<xref ref-type="bibr" rid="CR28">28</xref>].<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Best fitting results of PBFTPK models to efodipine data [<xref ref-type="bibr" rid="CR60">60</xref>]; each plot is accompanied by the corresponding percent absorbed <italic toggle="yes">versus</italic> time curve calculated using Eq. <xref rid="Equ6" ref-type="disp-formula">6</xref> from Ref. [<xref ref-type="bibr" rid="CR27">27</xref>]. The meaning of symbols can be found in [<xref ref-type="bibr" rid="CR60">60</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig8_HTML.jpg"/></fig></p><p id="Par27">All in all, the PBFTPK modelling work together with the modified in terms of the F.A.T. percent absorbed <italic toggle="yes">versus</italic> time plots, open a new physiologically based avenue of research for IVIVC. It is hoped that the adoption of the novel approach and the new strategy in the development of generics will gradually change the pessimistic views prevailing in the IVIVC field of research [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>].</p><sec id="FPar1"><title>Bioequivalence assessment</title><p id="Par28">Typically, therapeutic equivalence is declared when two products are bioequivalent. All bioequivalence studies rely on the 90% confidence interval test of the logarithmically (ln) transformed <inline-formula id="IEq7"><alternatives><tex-math id="d33e1677">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1682"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> and <italic toggle="yes">C</italic><sub>max</sub> mean values for the reference and test formulations; when the calculated 90% confidence interval for the ratio of (ln) transformed <inline-formula id="IEq8"><alternatives><tex-math id="d33e1697">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1702"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> and <italic toggle="yes">C</italic><sub>max</sub> mean values lies between 80 and 125%, bioequivalence is declared. Although, the statistical tests have been changed through the years from the inception of bioavailability in 1977 in FDA, the metrics <inline-formula id="IEq9"><alternatives><tex-math id="d33e1718">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1723"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> for the extent of absorption and <italic toggle="yes">C</italic><sub>max</sub> for the rate of absorption are used routinely since then [<xref ref-type="bibr" rid="CR5">5</xref>]. The use of both parameters <inline-formula id="IEq10"><alternatives><tex-math id="d33e1741">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1746"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> and <italic toggle="yes">C</italic><sub>max</sub> originates from the prevailing hypothesis of first-order absorption and the subsequent infinite absorption time [<xref ref-type="bibr" rid="CR15">15</xref>]. However, many publications have invalidated the use of <italic toggle="yes">C</italic><sub>max</sub> as a rate metric in bioequivalence studies, e.g., [<xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>]. We discuss below model-depended and model-independent (non-compartmental) approaches both based on the F.A.T. concept for the assessment of bioequivalence.<list list-type="simple"><list-item><label>i)</label><p id="Par29">Model-depended approach. When bioavailability was established by FDA in 1977, modelling in clinical pharmacology was in a pre-infancy period. Later, the development of non-linear mixed effect modelling approaches resulted in several relevant publications, e.g., [<xref ref-type="bibr" rid="CR68">68</xref>&#8211;<xref ref-type="bibr" rid="CR70">70</xref>]; the most recent publications in this field of research are focusing on what they call model-integrated evidence approaches for the analysis of bioequivalence data that have sparse sampling, e.g., [<xref ref-type="bibr" rid="CR71">71</xref>]. These studies [<xref ref-type="bibr" rid="CR68">68</xref>&#8211;<xref ref-type="bibr" rid="CR71">71</xref>] as well as all other model-depended approaches <italic toggle="yes">invariably and consistently utilize </italic><inline-formula id="IEq11"><alternatives><tex-math id="d33e1799">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1804"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula><italic toggle="yes"> and C</italic><sub>max</sub>
<italic toggle="yes">as pharmacokinetic end points</italic> in accord with the regulatory guidelines. In the light of the analytical power and the physiological character of PBFTPK models and in line with the spirit of the MIDD initiative [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>], we argue that a model depended approach based on the fitting results of the PBFTPK models to the experimental data can be used for the assessment of bioequivalence studies. We present an example of such an analysis in Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>A and B. Table <xref rid="Tab2" ref-type="table">2</xref> shows the extent and rate of absorption metrics derived from the fitting of PBFTPK models to cyclosporine bioequivalence data under fasted conditions [<xref ref-type="bibr" rid="CR15">15</xref>]. &#932;he areas under the curves were calculated with numerical integration up to the last experimental point.</p></list-item></list></p><p>
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Model-depended approach: PBFTPK model fittings to cyclosporine data under fasted conditions [<xref ref-type="bibr" rid="CR15">15</xref>] for reference (<bold>A</bold>) and test (<bold>B</bold>); R<sub>1</sub> denotes the rate of input. Model independent approach: Percent absorbed <italic toggle="yes">versus</italic> time curves (calculated using Eq. <xref rid="Equ6" ref-type="disp-formula">6</xref> from Ref. [<xref ref-type="bibr" rid="CR27">27</xref>]) for reference (<bold>C</bold>) and test (<bold>D</bold>) studied under fasted conditions [<xref ref-type="bibr" rid="CR15">15</xref>] and the corresponding plot (<bold>&#917;</bold>) for the ratio test/reference of the amount absorbed for the assessment of extent of absorption. The plot of the ratio (test/reference) of areas under the curve was&#160;calculated directly from the experimental data as a function of time (<bold>F</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO9" position="float" orientation="portrait" xlink:href="11095_2025_3878_Fig9_HTML.jpg"/></fig>
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Extent and Rate of Absorption Metrics and Their Estimates Derived from the Fitting Results of PBFTPK Models to Bioequivalence Data of Cyclosporine Studied Under Fasted Conditions [<xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Metrics:</th><th align="left" colspan="2" rowspan="1">Extent of absorption</th><th align="left" colspan="2" rowspan="1">Rate of absorption</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">Data set</th><th align="left" colspan="1" rowspan="1">Dose<break/>(mg)</th><th align="left" colspan="1" rowspan="1">
<inline-formula id="IEq12"><alternatives><tex-math id="d33e1921">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e1926"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula>
<break/>(h ng mL<sup>&#8722;1</sup>)</th><th align="left" colspan="1" rowspan="1">
<inline-formula id="IEq13"><alternatives><tex-math id="d33e1944">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e1949"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula>
<break/>(h ng mL<sup>&#8722;1</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub>&#8201;=&#8201;<italic toggle="yes">C</italic>(<italic toggle="yes">&#964;</italic>) (ng mL<sup>&#8722;1</sup>)</th><th align="left" colspan="1" rowspan="1">Input rate (ng mL<sup>&#8722;1</sup>&#160;h<sup>&#8722;1</sup>)</th><th align="left" colspan="1" rowspan="1">Duration (<italic toggle="yes">&#964;</italic>) (h)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cyclosporine Ref fasted</td><td align="left" colspan="1" rowspan="1">300</td><td align="left" colspan="1" rowspan="1">2815</td><td align="left" colspan="1" rowspan="1">845</td><td align="left" colspan="1" rowspan="1">486</td><td char="&#xB1;" align="char" colspan="1" rowspan="1"><p>282 &#177;&#8201;1<sup>a</sup></p><p>324 &#177;&#8201;15<sup>b</sup></p></td><td char="&#xB1;" align="char" colspan="1" rowspan="1"><p>2.86 &#177;&#8201;0.11<sup>a</sup></p><p>2.73 &#177;&#8201;0.08 <sup>b</sup></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Cyclosporine Test fasted</td><td align="left" colspan="1" rowspan="1">180</td><td align="left" colspan="1" rowspan="1">3394</td><td align="left" colspan="1" rowspan="1">634</td><td align="left" colspan="1" rowspan="1">923</td><td char="&#xB1;" align="char" colspan="1" rowspan="1"><p>822 &#177;&#8201;69<sup>a</sup></p><p>1140 &#177;&#8201;165<sup>b</sup></p></td><td char="&#xB1;" align="char" colspan="1" rowspan="1"><p>1.56 &#177;&#8201;0.15<sup>a</sup></p><p>1.37 &#177;&#8201;0.13<sup>b</sup></p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Derived from the fitting of PBFTPK models to the experimental data, Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A and B (model dependent approach)</p><p><sup>b</sup>Derived from the analysis of the percent absorbed <italic toggle="yes">versus</italic> time plots, Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>C and D (model independent approach)</p></table-wrap-foot></table-wrap>
</p><p>&#932;he higher bioavailability of the test formulation is obvious if one takes into account the different doses used. Correcting for dose, the ratios for the areas under the curve are <inline-formula id="IEq14"><alternatives><tex-math id="d33e2061">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{300}{180}\frac{{{\left[AUC\right]}_{0}^{\infty } }_{test}}{{{\left[AUC\right]}_{0}^{\infty }] }_{ref}}=2.0$$\end{document}</tex-math><mml:math id="d33e2066"><mml:mrow><mml:mfrac><mml:mn>300</mml:mn><mml:mn>180</mml:mn></mml:mfrac><mml:mfrac><mml:msub><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">test</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ref</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq14.gif"/></alternatives></inline-formula>, <inline-formula id="IEq15"><alternatives><tex-math id="d33e2105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{300}{180}\frac{{{\left[AUC\right]}_{0}^{\tau } }_{test}}{{{\left[AUC\right]}_{0}^{\tau } }_{ref}}=1.25$$\end{document}</tex-math><mml:math id="d33e2110"><mml:mrow><mml:mfrac><mml:mn>300</mml:mn><mml:mn>180</mml:mn></mml:mfrac><mml:mfrac><mml:msub><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">test</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mi mathvariant="italic">ref</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1.25</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq15.gif"/></alternatives></inline-formula>. The estimate of the relative bioavailability of the two formulations is higher using the <inline-formula id="IEq16"><alternatives><tex-math id="d33e2146">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e2151"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> than the <inline-formula id="IEq17"><alternatives><tex-math id="d33e2162">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e2167"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula>, while in previous studies of theophylline [<xref ref-type="bibr" rid="CR14">14</xref>] and digoxin [<xref ref-type="bibr" rid="CR72">72</xref>] the two metrics <inline-formula id="IEq18"><alternatives><tex-math id="d33e2185">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\infty }$$\end{document}</tex-math><mml:math id="d33e2190"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq1.gif"/></alternatives></inline-formula> and <inline-formula id="IEq19"><alternatives><tex-math id="d33e2201">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e2206"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula> provided equal bioavailability estimates in accord with the F.A.T. concept since the absorption process(es) terminates at time <italic toggle="yes">&#964;</italic>. This difference should be attributed to the interindividual variations in the cyclosporine clearance and the high first-pass effect (gut metabolism) [<xref ref-type="bibr" rid="CR73">73</xref>] of cyclosporine which is also affected by the significantly different input rates of the two formulations shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. In contrast, both theophylline and digoxin do not exhibit first-pass effect, while theophylline is a class I drug and digoxin is used in micrograms and their absorption is completed in less than 1.5 h [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]; therefore, the <inline-formula id="IEq20"><alternatives><tex-math id="d33e2233">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e2238"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula> values correspond to the fraction of drug absorbed up to time <italic toggle="yes">&#964;</italic>, which is also the bioavailable fraction. The use of <italic toggle="yes">C</italic><sub>max</sub> as a rate parameter has been severely criticised [<xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>] prior to the F.A.T. era. According to our findings [<xref ref-type="bibr" rid="CR14">14</xref>], <italic toggle="yes">C</italic><sub>max</sub> represents the concentration of cyclosporine at the end of the absorption process, <italic toggle="yes">C</italic>(<italic toggle="yes">&#964;</italic>). In fact, the test/reference ratio for <italic toggle="yes">C</italic><sub>max</sub> is 486/923 =&#8201;0.52; this value is almost twice as high as the corresponding ratios of the input rates calculated from the experimental data with two methodologies based on the F.A.T. concept listed in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, i.e., 282/822 =&#8201;0.34 and 324/1140 =&#8201;0.28. This is an additional [<xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>] piece of evidence that <italic toggle="yes">C</italic><sub>max</sub> does not represent the rate of cyclosporine absorption. It should be emphasized that the input rates reported in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> have rate units in full agreement with the spirit of rate as defined in the original FDA bioavailability document in 1977 [<xref ref-type="bibr" rid="CR5">5</xref>]. Finally, the duration of cyclosporine absorption from the reference formulation is longer (2.86 &#177;&#8201;0.11 h) than from the test formulation (1.56 &#177;&#8201;0.15 h).<list list-type="simple"><list-item><label>ii)</label><p id="Par32">Model-independent approach. The method relies on the modified Wagner-Nelson [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and Loo-Riegelman [<xref ref-type="bibr" rid="CR26">26</xref>] techniques, which are used for the construction of percent absorbed <italic toggle="yes">versus</italic> time plot as described in [<xref ref-type="bibr" rid="CR27">27</xref>]. The analysis of cyclosporine data, studied under fasted conditions in [<xref ref-type="bibr" rid="CR15">15</xref>], is presented in Fig. <xref rid="Fig9" ref-type="fig">9</xref>C, D, E and F; in all cases, the areas under the curves were calculated with numerical integration. The slope of the percent absorbed <italic toggle="yes">versus</italic> time bilinear plots (Fig. <xref rid="Fig9" ref-type="fig">9</xref>C and D) for the two formulations, corresponds to the rate of input and has been proposed as the metric for the assessment of rate of absorption in [<xref ref-type="bibr" rid="CR74">74</xref>]. The estimates of the input rate for the two formulations are listed in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>; quite similar results are obtained using the model-dependent and model independent methodologies since the pairwise statistical comparison of the input rates is not statistically significant. The constant ratio test/reference of the percent absorbed <italic toggle="yes">versus</italic> time plot at the plateau beyond the completion of cyclosporine absorption from the two formulations, Fig. <xref rid="Fig9" ref-type="fig">9</xref>E, corresponds to the relative bioavailability of the two formulations. An estimate for this constant ratio equal to 1.56 was calculated from the intersection of the back extrapolated horizontal line and the <italic toggle="yes">y</italic>-axis of Fig. <xref rid="Fig9" ref-type="fig">9</xref>E. This value can be corrected in terms of the doses used, 1.56 &#215;&#8201;(300/180) =&#8201;2.6. This estimate differs from the estimate 2.0 derived from the model-dependent approach. This difference should be attributed to the different methodology used in the two approaches for the numerical integration (trapezoidal rule) of the areas under the curves. In the model-dependent approach the areas were calculated directly from the experimental data up to the last time point and therefore an unbiased estimate was derived for the relative bioavailability, 2.0. In the model independent approach, the calculation relies first on the estimate of the elimination rate constant, <italic toggle="yes">k</italic><sub>10</sub> followed by an iterative calculation of drug concentration in the peripheral compartment, which affects the final estimate for the relative bioavailability. A visual check plot for the pharmacokinetic characteristics and the bioequivalence assessment can be based on Fig. <xref rid="Fig9" ref-type="fig">9</xref>&#8201;F, which shows the ratio of the areas of the two formulations calculated directly from the experimental data as a function of time; this plot shows clearly the end of the absorption processes and the slight decline as a function of time of the final limb of the curve indicating the larger clearance of the individuals receiving the test formulation throughout the elimination phase of the two formulations, i.e., beyond the completion of absorption process. The estimate of the ratio of the areas at the last datum point is 1.202, which if corrected in terms of dose is identical to the relative bioavailability estimate derived from the model-dependent approach, i.e., 1.202 &#215;&#8201;(300/180) =&#8201;2.0. However, the estimates for the duration of cyclosporine absorption from the reference formulation is longer (2.73 &#177;&#8201;0.08 h) than from the test formulation (1.37 &#177;&#8201;0.13 h). Overall, similar estimates for the duration of cyclosporine absorption are derived from the two methodologies, Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p></list-item></list></p><p>Important conclusions can be derived from this analysis concerning the assessment of extent and rate of absorption in the assessment of bioequivalence. Although the <inline-formula id="IEq21"><alternatives><tex-math id="d33e2368">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e2373"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula> metric seems to be ideal for the assessment of the extent of absorption [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], the present work underscores that <inline-formula id="IEq22"><alternatives><tex-math id="d33e2390">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[AUC\right]}_{0}^{\tau }$$\end{document}</tex-math><mml:math id="d33e2395"><mml:msubsup><mml:mfenced close="]" open="["><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mfenced><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq13.gif"/></alternatives></inline-formula> should not be used when first-pass effect phenomena are operating and/or interindividual variations in the clearance of the two treatments are observed. The model dependent approach opens a new avenue for rate considerations in bioequivalence. This is so since the PBFTPK models provide the number, the magnitude and the duration for each one of the absorption stages. In parallel, the model independent approach provides an equally well estimation of the rate of absorption. In addition, the ratio of areas as a function of time plot gives an insight for the end of absorption process as well as the relative magnitude of clearance of the two treatments. When rate was introduced in 1977, the term was obscure, not well defined [<xref ref-type="bibr" rid="CR75">75</xref>] and remained as such since a single fictitious first-order absorption rate constant was (is) used to quantify oral drug absorption. In the light of F.A.T. advances the concept of rate in bioequivalence studies should be reconsidered and the use of <italic toggle="yes">C</italic><sub>max</sub> as a rate metric should be discontinued.</p></sec></sec></sec><sec id="Sec7"><title>Regulatory Implications</title><p id="Par34">All guidelines of regulatory Agencies rely on the dogma &#8220;Guidelines are scientifically based&#8217;. This work and the previous studies [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR68">68</xref>] on the F.A.T. concept, point to the fact that many scientific views require re-consideration and the use of PBFTPK models in pharmacokinetics and pharmacometrics instead of the first-order absorption models should be adopted. Plausibly, the PBFTPK models should be quoted among the modeling and simulation approaches in the &#8220;ICH M15 Guideline on general principles for model informed drug development&#8221;. This will gradually place an end to the perpetuation of infinite oral drug absorption fallacy in pharmacokinetics and pharmacometrics research as well as the relevant dossier submitted for approval to FDA and EMA. In the same vein, the Drug Agencies should consider the results of the present study for the guidelines associated with IVIVC, bioavailability and bioequivalence. Although these guidelines have been evolving for 50 years now and they are very well-established today, a dialogue should start in view of the physiologically relevant F.A.T. concept and the associated applications of the PBFTPK models delineated above.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par35">The current thinking in oral drug absorption is not in line with the finite time character of the drug processes taking place under <italic toggle="yes">in vivo</italic> conditions. The application of the physiologically sound F.A.T. concept coupled with the analysis of pharmacokinetic data with the relevant PBFTPK models are more akin to <italic toggle="yes">in vivo</italic> conditions and therefore capture the dynamics of drug absorption processes. These approaches can be applied successfully in all phases of drug/generics development and justify the changes required in the strategy of drug and generics development. Relevant regulatory changes are anticipated.</p></sec></body><back><app-group><app id="App1"><sec id="Sec9"><title>Appendix</title><p id="Par37">Equations&#160;<xref rid="Equ3" ref-type="disp-formula">1</xref>A and <xref rid="Equ4" ref-type="disp-formula">2</xref>A describe the drug concentration as a function of time following zero-order input kinetics for time <italic toggle="yes">&#964;</italic> assuming one-compartment model disposition<disp-formula id="Equ3"><label>1A</label><alternatives><tex-math id="d33e2481">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{array}{cc}C\left(t\right)=\frac{FD}{{V}_{\text{d}}{k}_{\text{el}}\tau }\left(1-{\text{e}}^{{-k}_{\text{el}}t}\right)&amp; \text{for }t \le \tau \end{array}$$\end{document}</tex-math><mml:math id="d33e2487" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>C</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">FD</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mtext>d</mml:mtext></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>-</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mtext>el</mml:mtext></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mfenced></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mtext>for</mml:mtext><mml:mspace width="0.333333em"/><mml:mi>t</mml:mi><mml:mo>&#8804;</mml:mo><mml:mi>&#964;</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ3.gif"/></alternatives></disp-formula><disp-formula id="Equ4"><label>2A</label><alternatives><tex-math id="d33e2530">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{array}{cc}C\left(t\right)=C\left(\tau \right){\text{e}}^{-{k}_{\text{el}}\left(t-\tau \right)}&amp; \text{for }t &gt; \tau \end{array}$$\end{document}</tex-math><mml:math id="d33e2536" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>C</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mfenced close=")" open="("><mml:mi>&#964;</mml:mi></mml:mfenced><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mi>&#964;</mml:mi></mml:mfenced></mml:mrow></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mtext>for</mml:mtext><mml:mspace width="0.333333em"/><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:mi>&#964;</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ4.gif"/></alternatives></disp-formula>where <italic toggle="yes">D</italic> is the drug dose, <italic toggle="yes">F</italic> is the bioavailable fraction, <italic toggle="yes">V</italic><sub>d</sub> is the volume of distribution and <italic toggle="yes">k</italic><sub>el</sub> is the elimination rate constant. The amount of drug eliminated up to time <italic toggle="yes">&#964;</italic>, <italic toggle="yes">Q</italic><sub>el</sub>(<italic toggle="yes">&#964;</italic>) is<disp-formula id="Equ5"><label>3A</label><alternatives><tex-math id="d33e2596">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${Q}_{\text{el}}(\tau )={V}_{\text{d}}{\int }_{0}^{\tau }{k}_{\text{el}}C(t)\text{d}t={V}_{\text{d}}{\int }_{0}^{\tau }{k}_{\text{el}}\frac{FD}{{{V}_{\text{d}}k}_{\text{el}}\tau }\left(1-{\text{e}}^{-{k}_{el}t}\right)\text{d}t=\frac{FD}{\tau }\left(\tau -0\right)+\frac{FD}{{k}_{\text{el}}\tau }\left(1-{\text{e}}^{-{k}_{\text{el}}\tau }\right)=FD\left[1-\frac{1-{\text{e}}^{-{k}_{\text{el}}\tau }}{{k}_{\text{el}}\tau }\right]$$\end{document}</tex-math><mml:math id="d33e2602" display="block"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mtext>d</mml:mtext></mml:msub><mml:msubsup><mml:mo>&#8747;</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mtext>d</mml:mtext></mml:msub><mml:msubsup><mml:mo>&#8747;</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#964;</mml:mi></mml:msubsup><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">FD</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mtext>d</mml:mtext></mml:msub><mml:mi>k</mml:mi></mml:mrow><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">el</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mfenced><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">FD</mml:mi></mml:mrow><mml:mi>&#964;</mml:mi></mml:mfrac><mml:mfenced close=")" open="("><mml:mi>&#964;</mml:mi><mml:mo>-</mml:mo><mml:mn>0</mml:mn></mml:mfenced><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">FD</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:msup></mml:mfenced><mml:mo>=</mml:mo><mml:mi>F</mml:mi><mml:mi>D</mml:mi><mml:mfenced close="]" open="["><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ5.gif"/></alternatives></disp-formula></p><p id="Par38">Therefore, the amount of drug in the body at time <italic toggle="yes">&#964;</italic> is equal to <inline-formula id="IEq23"><alternatives><tex-math id="d33e2739">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$FD-{Q}_{\text{el}}(\tau )$$\end{document}</tex-math><mml:math id="d33e2744"><mml:mrow><mml:mi>F</mml:mi><mml:mi>D</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq23.gif"/></alternatives></inline-formula>. The corresponding area <inline-formula id="IEq24"><alternatives><tex-math id="d33e2760">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[\text{AUC}\right]}_{\uptau }^{\infty }$$\end{document}</tex-math><mml:math id="d33e2765"><mml:msubsup><mml:mfenced close="]" open="["><mml:mtext>AUC</mml:mtext></mml:mfenced><mml:mrow><mml:mi mathvariant="normal">&#964;</mml:mi></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11095_2025_3878_Article_IEq24.gif"/></alternatives></inline-formula> is equal to<disp-formula id="Equ6"><label>4A</label><alternatives><tex-math id="d33e2775">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\left[\text{AUC}\right]}_{\tau }^{\infty }=\frac{FD-{Q}_{\text{el}}(\tau )}{CL}$$\end{document}</tex-math><mml:math id="d33e2781" display="block"><mml:mrow><mml:msubsup><mml:mfenced close="]" open="["><mml:mtext>AUC</mml:mtext></mml:mfenced><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow><mml:mi>&#8734;</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mi>D</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mtext>el</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="11095_2025_3878_Article_Equ6.gif"/></alternatives></disp-formula>which is Eq.&#160;<xref rid="Equ1" ref-type="disp-formula">1</xref> of the text.</p></sec></app></app-group><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are indebted to Professor Oscar Della Pasqua, University College London, for his scientific advice.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>P.M. conceptualization, writing draft, coordinating project; A.A.T. data analysis, figure drawing, draft editing; S.S.H. abacavir data analysis, K.K. fractal kinetics data analysis.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by HEAL-Link Greece. No funding was used for this work.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Conflicts of Interest</title><p id="Par36">The authors declare no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrer</surname><given-names>E</given-names></name><name name-style="western"><surname>Baty</surname><given-names>F</given-names></name><name name-style="western"><surname>Kehren</surname><given-names>J</given-names></name><name name-style="western"><surname>Chibout</surname><given-names>SD</given-names></name><name name-style="western"><surname>Brutsche</surname><given-names>M</given-names></name></person-group><article-title>Past, present and future of gene expression-tailored therapy for lung cancer</article-title><source>Per Med</source><year>2006</year><volume>3</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.2217/17410541.3.2.165</pub-id><pub-id pub-id-type="pmid">29793291</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Marrer E, Baty F, Kehren J, Chibout SD, Brutsche M. Past, present and future of gene expression-tailored therapy for lung cancer. Per Med. 2006;3:165&#8211;75. 10.2217/17410541.3.2.165.<pub-id pub-id-type="pmid">29793291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/17410541.3.2.165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>KW</given-names></name><name name-style="western"><surname>Bermseok</surname><given-names>O</given-names></name></person-group><article-title>Overview of personalized medicine in the disease genomic era</article-title><source>BMB Rep</source><year>2010</year><volume>43</volume><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2010.43.10.643</pub-id><pub-id pub-id-type="pmid">21034525</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hong KW, Bermseok O. Overview of personalized medicine in the disease genomic era. BMB Rep. 2010;43:643&#8211;8. 10.5483/BMBRep.2010.43.10.643.<pub-id pub-id-type="pmid">21034525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5483/BMBRep.2010.43.10.643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitti</surname><given-names>TG</given-names></name><name name-style="western"><surname>Banes</surname><given-names>D</given-names></name><name name-style="western"><surname>Byers</surname><given-names>TE</given-names></name></person-group><article-title>Bioavailability of Digoxin</article-title><source>N Engl J Med</source><year>1971</year><volume>285</volume><fpage>1433</fpage><pub-id pub-id-type="doi">10.1056/nejm197112162852512</pub-id><pub-id pub-id-type="pmid">5121213</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Vitti TG, Banes D, Byers TE. Bioavailability of Digoxin. N Engl J Med. 1971;285:1433. 10.1056/nejm197112162852512.<pub-id pub-id-type="pmid">5121213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197112162852512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skelly</surname><given-names>JP</given-names></name></person-group><article-title>The history of biopharmaceutics in Food and Drug Administration 1968&#8211;1993</article-title><source>AAPS J</source><year>2010</year><volume>12</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1208/s12248-009-9154-8</pub-id><pub-id pub-id-type="pmid">19936940</pub-id><pub-id pub-id-type="pmcid">PMC2811644</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Skelly JP. The history of biopharmaceutics in Food and Drug Administration 1968&#8211;1993. AAPS J. 2010;12:44&#8211;50. 10.1208/s12248-009-9154-8.<pub-id pub-id-type="pmid">19936940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-009-9154-8</pub-id><pub-id pub-id-type="pmcid">PMC2811644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">FDA. On January 7, 1977, FDA issued final regulations in part 320 (21 CFR 320) establishing definitions and requirements for BA and BE studies (42 FR 1624).</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Zhao L, Peck CC. Impact of clinical pharmacology on the modernization of drug development and regulation. In: Macheras P, editor. Advances in pharmacokinetics and pharmacodynamics, Springer; 2023. p. 165&#8211;202. 10.1007/978-3-031-29541-6_7.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Dorlo TPC, Svensson EM. Pharmacokinetic-pharmacodynamic modeling and simulation in clinical practice and studies.&#160;In: Macheras P, editor. Advances in pharmacokinetics and pharmacodynamics. AAPS introductions in the pharmaceutical sciences. vol 9. Springer, Cham; 2023. p. 109&#8211;135. 10.1007/978-3-031-29541-6_5.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ahadpour</surname><given-names>M</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name></person-group><article-title>Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends</article-title><source>AAPS J</source><year>2021</year><volume>23</volume><issue>3</issue><fpage>54</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00563-3</pub-id><pub-id pub-id-type="pmid">33846878</pub-id><pub-id pub-id-type="pmcid">PMC8041391</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Liu Q, Ahadpour M, Rocca M, Huang SM. Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends. AAPS J. 2021;23(3):54. 10.1208/s12248-021-00563-3.<pub-id pub-id-type="pmid">33846878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-021-00563-3</pub-id><pub-id pub-id-type="pmcid">PMC8041391</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dost</surname><given-names>FH</given-names></name></person-group><source>Der Blutspiegel-Kinetic der Konzentrationsabl&#228;ufe in der Kreislauffl&#252;ssigkeit</source><year>1953</year><publisher-loc>Leipzig</publisher-loc><publisher-name>G. Thieme</publisher-name></element-citation><mixed-citation id="mc-CR9" publication-type="book">Dost FH. Der Blutspiegel-Kinetic der Konzentrationsabl&#228;ufe in der Kreislauffl&#252;ssigkeit. Leipzig: G. Thieme; 1953.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dost</surname><given-names>FH</given-names></name></person-group><source>Grundlagen der Pharmakokinetik</source><year>1968</year><publisher-loc>Leipzig</publisher-loc><publisher-name>G. Thieme</publisher-name></element-citation><mixed-citation id="mc-CR10" publication-type="book">Dost FH. Grundlagen der Pharmakokinetik. Leipzig: G. Thieme; 1968.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>G</given-names></name></person-group><article-title>Wagner, History of pharmacokinetics</article-title><source>Pharmacol Ther</source><year>1981</year><volume>12</volume><issue>3</issue><fpage>537</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(81)90097-8</pub-id><pub-id pub-id-type="pmid">7025032</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">John G. Wagner, History of pharmacokinetics. Pharmacol Ther. 1981;12(3):537&#8211;62. 10.1016/0163-7258(81)90097-8.<pub-id pub-id-type="pmid">7025032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0163-7258(81)90097-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name><name name-style="western"><surname>Chryssafidis</surname><given-names>P</given-names></name></person-group><article-title>Revising pharmacokinetics of oral drug absorption: I Models based on biopharmaceutical/physiological and finite absorption time concepts</article-title><source>Pharm Res.</source><year>2020</year><volume>37</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1007/s11095-020-02894-w</pub-id><pub-id pub-id-type="pmid">32888087</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Macheras P, Chryssafidis P. Revising pharmacokinetics of oral drug absorption: I Models based on biopharmaceutical/physiological and finite absorption time concepts. Pharm Res. 2020;37:187. 10.1007/s11095-020-02894-w. (Erratum Pharm Res 2020;37:206. 10.1007/s11095-020-02935-4).<pub-id pub-id-type="pmid">32888087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-020-02894-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name></person-group><article-title>The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2023</year><volume>50</volume><fpage>5</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s10928-022-09832-w</pub-id><pub-id pub-id-type="pmid">36369406</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Macheras P, Tsekouras AA. The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics. J Pharmacokinet Pharmacodyn. 2023;50:5&#8211;10. 10.1007/s10928-022-09832-w.<pub-id pub-id-type="pmid">36369406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10928-022-09832-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chryssafidis</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Revising pharmacokinetics of oral drug absorption: II bioavailability bioequivalence considerations</article-title><source>Pharm Res</source><year>2021</year><volume>38</volume><fpage>1345</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03078-w</pub-id><pub-id pub-id-type="pmid">34341958</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Chryssafidis P, Tsekouras AA, Macheras P. Revising pharmacokinetics of oral drug absorption: II bioavailability bioequivalence considerations. Pharm Res. 2021;38:1345&#8211;56. 10.1007/s11095-021-03078-w.<pub-id pub-id-type="pmid">34341958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-021-03078-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chryssafidis</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models</article-title><source>Pharm Res</source><year>2022</year><volume>39</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1007/s11095-022-03230-0</pub-id><pub-id pub-id-type="pmid">35378697</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chryssafidis P, Tsekouras AA, Macheras P. Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models. Pharm Res. 2022;39:691&#8211;701. 10.1007/s11095-022-03230-0.<pub-id pub-id-type="pmid">35378697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-022-03230-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sager</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ragueneau-Majlessi</surname><given-names>I</given-names></name><name name-style="western"><surname>Isoherranen</surname><given-names>N</given-names></name></person-group><article-title>Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification</article-title><source>Drug Metab Dispos</source><year>2015</year><volume>43</volume><issue>11</issue><fpage>1823</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1124/dmd.115.065920</pub-id><pub-id pub-id-type="pmid">26296709</pub-id><pub-id pub-id-type="pmcid">PMC4613950</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43(11):1823&#8211;37. 10.1124/dmd.115.065920.<pub-id pub-id-type="pmid">26296709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.065920</pub-id><pub-id pub-id-type="pmcid">PMC4613950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lappin</surname><given-names>G</given-names></name><name name-style="western"><surname>Garner</surname><given-names>RC</given-names></name></person-group><article-title>The use of accelerator mass spectrometry to obtain early human ADME/PK data</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2005</year><volume>1</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1517/17425255.1.1.23</pub-id><pub-id pub-id-type="pmid">16922650</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lappin G, Garner RC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metab Toxicol. 2005;1(1):23&#8211;31. 10.1517/17425255.1.1.23.<pub-id pub-id-type="pmid">16922650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.1.1.23</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaarg</surname><given-names>A</given-names></name><name name-style="western"><surname>Menon</surname><given-names>R</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bien</surname><given-names>J</given-names></name><name name-style="western"><surname>Elkinton</surname><given-names>T</given-names></name><name name-style="western"><surname>Grieme</surname><given-names>T</given-names></name><name name-style="western"><surname>Asmus</surname><given-names>LR</given-names></name><name name-style="western"><surname>Salem</surname><given-names>AH</given-names></name></person-group><article-title>A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic</article-title><source>Clin Transl Sci</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1111/cts.13144</pub-id><pub-id pub-id-type="pmid">34416076</pub-id><pub-id pub-id-type="pmcid">PMC8742638</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Alaarg A, Menon R, Rizzo D, Liu Y, Bien J, Elkinton T, Grieme T, Asmus LR, Salem AH. A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic. Clin Transl Sci. 2022;15(1):244&#8211;54. 10.1111/cts.13144.<pub-id pub-id-type="pmid">34416076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13144</pub-id><pub-id pub-id-type="pmcid">PMC8742638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svendsen</surname><given-names>P</given-names></name><name name-style="western"><surname>El-Galaly</surname><given-names>TC</given-names></name><name name-style="western"><surname>Dybk&#230;r</surname><given-names>K</given-names></name><name name-style="western"><surname>B&#248;gsted</surname><given-names>M</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>MB</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>A</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>P</given-names></name><name name-style="western"><surname>Johnsen</surname><given-names>HE</given-names></name></person-group><article-title>The application of human phase 0 microdosing trials: A systematic review and perspectives</article-title><source>Leuk Lymphoma</source><year>2016</year><volume>57</volume><issue>6</issue><fpage>1281</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.3109/10428194.2015.1101097</pub-id><pub-id pub-id-type="pmid">26428262</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Svendsen P, El-Galaly TC, Dybk&#230;r K, B&#248;gsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE. The application of human phase 0 microdosing trials: A systematic review and perspectives. Leuk Lymphoma. 2016;57(6):1281&#8211;90. 10.3109/10428194.2015.1101097.<pub-id pub-id-type="pmid">26428262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/10428194.2015.1101097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roffel</surname><given-names>AF</given-names></name><name name-style="western"><surname>van Hoogdalem</surname><given-names>EJ</given-names></name></person-group><article-title>The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future</article-title><source>Front Pharmacol</source><year>2024</year><volume>18</volume><issue>15</issue><fpage>1369079</fpage><pub-id pub-id-type="doi">10.3389/fphar.2024.1369079</pub-id><pub-id pub-id-type="pmcid">PMC10982362</pub-id><pub-id pub-id-type="pmid">38562464</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Roffel AF, van Hoogdalem EJ. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future. Front Pharmacol. 2024;18(15):1369079. 10.3389/fphar.2024.1369079.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1369079</pub-id><pub-id pub-id-type="pmcid">PMC10982362</pub-id><pub-id pub-id-type="pmid">38562464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lappin</surname><given-names>G</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name><name name-style="western"><surname>Garner</surname><given-names>RC</given-names></name></person-group><article-title>The use of isotopes in the determination of absolute bioavailability of drugs in humans</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2006</year><volume>2</volume><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1517/17425255.2.3.419</pub-id><pub-id pub-id-type="pmid">16863443</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol. 2006;2:419&#8211;27. 10.1517/17425255.2.3.419.<pub-id pub-id-type="pmid">16863443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2.3.419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lappin</surname><given-names>G</given-names></name><name name-style="western"><surname>Noveck</surname><given-names>R</given-names></name><name name-style="western"><surname>Burt</surname><given-names>T</given-names></name></person-group><article-title>Microdosing and drug development: past, present and future</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2013</year><volume>9</volume><fpage>817</fpage><pub-id pub-id-type="doi">10.1517/17425255.2013.786042</pub-id><pub-id pub-id-type="pmid">23550938</pub-id><pub-id pub-id-type="pmcid">PMC4532546</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013;9:817. 10.1517/17425255.2013.786042.<pub-id pub-id-type="pmid">23550938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2013.786042</pub-id><pub-id pub-id-type="pmcid">PMC4532546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raje</surname><given-names>S</given-names></name><name name-style="western"><surname>Callegari</surname><given-names>E</given-names></name><name name-style="western"><surname>Sahasrabudhe</surname><given-names>V</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fluhler</surname><given-names>E</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Schildknegt</surname><given-names>K</given-names></name><name name-style="western"><surname>Matschke</surname><given-names>K</given-names></name><name name-style="western"><surname>Alvey</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Fountaine</surname><given-names>R</given-names></name><name name-style="western"><surname>Saur</surname><given-names>D</given-names></name><name name-style="western"><surname>Terra</surname><given-names>SG</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L</given-names></name><name name-style="western"><surname>Gaunt</surname><given-names>D</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>DL</given-names></name></person-group><article-title>Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin</article-title><source>Clin Transl Sci</source><year>2018</year><volume>11</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1111/cts.12549</pub-id><pub-id pub-id-type="pmid">29575530</pub-id><pub-id pub-id-type="pmcid">PMC6039199</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Raje S, Callegari E, Sahasrabudhe V, Vaz A, Shi H, Fluhler E, Woolf EJ, Schildknegt K, Matschke K, Alvey C, Zhou S, Papadopoulos D, Fountaine R, Saur D, Terra SG, Stevens L, Gaunt D, Cutler DL. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin. Clin Transl Sci. 2018;11:405&#8211;11. 10.1111/cts.12549.<pub-id pub-id-type="pmid">29575530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.12549</pub-id><pub-id pub-id-type="pmcid">PMC6039199</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>JG</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>E</given-names></name></person-group><article-title>Percent absorbed time plots derived from blood level and/or urinary excretion data</article-title><source>J Pharm Sci</source><year>1963</year><volume>52</volume><fpage>610</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1002/jps.2600520629</pub-id><pub-id pub-id-type="pmid">13998253</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wagner JG, Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963;52:610&#8211;1. 10.1002/jps.2600520629.<pub-id pub-id-type="pmid">13998253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600520629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>JG</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>E</given-names></name></person-group><article-title>The kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug</article-title><source>J Pharm Sci</source><year>1964</year><volume>53</volume><fpage>1392</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1002/jps.2600531126</pub-id><pub-id pub-id-type="pmid">14253604</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wagner JG, Nelson E. The kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392&#8211;403. 10.1002/jps.2600531126.<pub-id pub-id-type="pmid">14253604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600531126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>JCK</given-names></name><name name-style="western"><surname>Riegelman</surname><given-names>S</given-names></name></person-group><article-title>New method for calculating the intrinsic absorption rate of drugs</article-title><source>J Pharm Sci</source><year>1968</year><volume>57</volume><fpage>918</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1002/jps.2600570602</pub-id><pub-id pub-id-type="pmid">5671338</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968;57:918&#8211;28. 10.1002/jps.2600570602.<pub-id pub-id-type="pmid">5671338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600570602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimpertis</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption</article-title><source>Pharm Res</source><year>2023</year><volume>40</volume><fpage>2167</fpage><lpage>2175</lpage><pub-id pub-id-type="doi">10.1007/s11095-023-03578-x</pub-id><pub-id pub-id-type="pmid">37537424</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Alimpertis N, Tsekouras AA, Macheras P. Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption. Pharm Res. 2023;40:2167&#8211;75. 10.1007/s11095-023-03578-x.<pub-id pub-id-type="pmid">37537424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-023-03578-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimpertis</surname><given-names>N</given-names></name><name name-style="western"><surname>Simitopoulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>A</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>IVIVC revised</article-title><source>Pharm Res</source><year>2024</year><volume>41</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s11095-024-03653-x</pub-id><pub-id pub-id-type="pmid">38191705</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Alimpertis N, Simitopoulos A, Tsekouras A, Macheras P. IVIVC revised. Pharm Res. 2024;41:235&#8211;46. 10.1007/s11095-024-03653-x.<pub-id pub-id-type="pmid">38191705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-024-03653-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Chae J, Seo J, Mahat B, Yun HY, Baek I, Lee B, Kim D, Kwon K. A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Developm Ind Pharmacy. 2013;40:1325&#8211;9. 10.3109/03639045.2013.819880.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03639045.2013.819880</pub-id><pub-id pub-id-type="pmid">23886303</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porras</surname><given-names>AG</given-names></name><name name-style="western"><surname>Holland</surname><given-names>SD</given-names></name><name name-style="western"><surname>Gertz</surname><given-names>BJ</given-names></name></person-group><article-title>Pharmacokinetics of alendronate</article-title><source>Clin Pharmacokinet</source><year>1999</year><volume>36</volume><issue>5</issue><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.2165/00003088-199936050-00002</pub-id><pub-id pub-id-type="pmid">10384857</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999;36(5):315&#8211;28. 10.2165/00003088-199936050-00002.<pub-id pub-id-type="pmid">10384857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199936050-00002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bredberg</surname><given-names>U</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Borgstr&#246;m</surname><given-names>L</given-names></name></person-group><article-title>A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans</article-title><source>Clin Pharmacol Ther</source><year>1992</year><volume>52</volume><issue>3</issue><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/clpt.1992.136</pub-id><pub-id pub-id-type="pmid">1526079</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bredberg U, Karlsson MO, Borgstr&#246;m L. A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. Clin Pharmacol Ther. 1992;52(3):239&#8211;48. 10.1038/clpt.1992.136.<pub-id pub-id-type="pmid">1526079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1992.136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Bredberg</surname><given-names>U</given-names></name></person-group><article-title>Estimation of bioavailability on a single occasion after semisimultaneous drug administration</article-title><source>Pharm Res</source><year>1989</year><volume>6</volume><issue>9</issue><fpage>817</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1023/a:1015939917646</pub-id><pub-id pub-id-type="pmid">2813280</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Karlsson MO, Bredberg U. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm Res. 1989;6(9):817&#8211;21. 10.1023/a:1015939917646.<pub-id pub-id-type="pmid">2813280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1015939917646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kvitne</surname><given-names>KE</given-names></name><name name-style="western"><surname>Drevland</surname><given-names>OM</given-names></name><name name-style="western"><surname>Haugli</surname><given-names>N</given-names></name><name name-style="western"><surname>Skadberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Zar&#233;</surname><given-names>HK</given-names></name><name name-style="western"><surname>&#197;sberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Robertsen</surname><given-names>I</given-names></name></person-group><article-title>Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals</article-title><source>Clin Pharmacokinet</source><year>2023</year><volume>62</volume><issue>7</issue><fpage>981</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1007/s40262-023-01257-z</pub-id><pub-id pub-id-type="pmid">37162619</pub-id><pub-id pub-id-type="pmcid">PMC10338616</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kvitne KE, Drevland OM, Haugli N, Skadberg E, Zar&#233; HK, &#197;sberg A, Robertsen I. Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals. Clin Pharmacokinet. 2023;62(7):981&#8211;7. 10.1007/s40262-023-01257-z.<pub-id pub-id-type="pmid">37162619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01257-z</pub-id><pub-id pub-id-type="pmcid">PMC10338616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokoumetzidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Papadopoulou</surname><given-names>V</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function</article-title><source>Pharm Res</source><year>2006</year><volume>23</volume><issue>2</issue><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s11095-006-9093-3</pub-id><pub-id pub-id-type="pmid">16421665</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dokoumetzidis A, Papadopoulou V, Macheras P. Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. Pharm Res. 2006;23(2):256&#8211;61. 10.1007/s11095-006-9093-3.<pub-id pub-id-type="pmid">16421665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-006-9093-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koolen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name></person-group><article-title>Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>87</volume><issue>1</issue><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/clpt.2009.233</pub-id><pub-id pub-id-type="pmid">19924122</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther. 2010;87(1):126&#8211;9. 10.1038/clpt.2009.233.<pub-id pub-id-type="pmid">19924122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2009.233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Soon JA, Franchini F, IJzerman MJ, McArthur GA. Leveraging the potential for deintensification in cancer care. Nat Cancer. 2024. 10.1038/s43018-024-00827-9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-024-00827-9</pub-id><pub-id pub-id-type="pmid">39304773</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soulele</surname><given-names>K</given-names></name><name name-style="western"><surname>Karampelas</surname><given-names>T</given-names></name><name name-style="western"><surname>Tamvakopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><source>Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation Pharm Res</source><year>2021</year><volume>38</volume><fpage>1419</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03085-x</pub-id><pub-id pub-id-type="pmid">34382143</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Soulele K, Karampelas T, Tamvakopoulos C, Macheras P. Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation Pharm Res. 2021;38:1419&#8211;28. 10.1007/s11095-021-03085-x.<pub-id pub-id-type="pmid">34382143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-021-03085-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coldani</surname><given-names>ME</given-names></name><name name-style="western"><surname>Palugan</surname><given-names>L</given-names></name><name name-style="western"><surname>Foppoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Cerea</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>JF</given-names></name></person-group><article-title>Evaluation of different techniques for wet granulation and pelletization processes using milk as innovative pharmaceutical excipient for pediatric use</article-title><source>Int J Pharm</source><year>2024</year><volume>13</volume><issue>666</issue><fpage>124836</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124836</pub-id><pub-id pub-id-type="pmid">39406302</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Coldani ME, Palugan L, Foppoli A, Cerea M, Pinto JF. Evaluation of different techniques for wet granulation and pelletization processes using milk as innovative pharmaceutical excipient for pediatric use. Int J Pharm. 2024;13(666):124836. 10.1016/j.ijpharm.2024.124836.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2024.124836</pub-id><pub-id pub-id-type="pmid">39406302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soulele</surname><given-names>K</given-names></name><name name-style="western"><surname>Karalis</surname><given-names>V</given-names></name></person-group><article-title>On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe</article-title><source>Xenobiotica</source><year>2019</year><volume>49</volume><issue>4</issue><fpage>446</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1080/00498254.2018.1463117</pub-id><pub-id pub-id-type="pmid">29629619</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Soulele K, Karalis V. On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Xenobiotica. 2019;49(4):446&#8211;56. 10.1080/00498254.2018.1463117.<pub-id pub-id-type="pmid">29629619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498254.2018.1463117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>M</given-names></name><name name-style="western"><surname>D'Argenio</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>W</given-names></name></person-group><article-title>Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin</article-title><source>Pharm Res</source><year>2022</year><volume>39</volume><issue>12</issue><fpage>3293</fpage><lpage>3300</lpage><pub-id pub-id-type="doi">10.1007/s11095-022-03397-6</pub-id><pub-id pub-id-type="pmid">36163409</pub-id><pub-id pub-id-type="pmcid">PMC9780127</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Weiss M, D&#8217;Argenio DZ, Siegmund W. Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin. Pharm Res. 2022;39(12):3293&#8211;300. 10.1007/s11095-022-03397-6.<pub-id pub-id-type="pmid">36163409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-022-03397-6</pub-id><pub-id pub-id-type="pmcid">PMC9780127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#233;nin</surname><given-names>E</given-names></name><name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Standing</surname><given-names>JF</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model</article-title><source>AAPS J</source><year>2012</year><volume>14</volume><issue>2</issue><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9324-y</pub-id><pub-id pub-id-type="pmid">22286919</pub-id><pub-id pub-id-type="pmcid">PMC3326175</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">H&#233;nin E, Bergstrand M, Standing JF, Karlsson MO. A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model. AAPS J. 2012;14(2):155&#8211;63. 10.1208/s12248-012-9324-y.<pub-id pub-id-type="pmid">22286919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-012-9324-y</pub-id><pub-id pub-id-type="pmcid">PMC3326175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Remsberg</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sayre</surname><given-names>CL</given-names></name><name name-style="western"><surname>Laird Forrest</surname><given-names>M</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name></person-group><article-title>Flip-flop pharmacokinetics delivering a reversal of disposition: challenges and opportunities during drug development</article-title><source>Ther Deliv</source><year>2011</year><volume>2</volume><fpage>643</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.4155/tde.11.19</pub-id><pub-id pub-id-type="pmid">21837267</pub-id><pub-id pub-id-type="pmcid">PMC3152312</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Yanez JA, Remsberg CM, Sayre CL, Laird Forrest M, Davies NM. Flip-flop pharmacokinetics delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2:643&#8211;72. 10.4155/tde.11.19.<pub-id pub-id-type="pmid">21837267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/tde.11.19</pub-id><pub-id pub-id-type="pmcid">PMC3152312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuan</surname><given-names>IHS</given-names></name><name name-style="western"><surname>Wright</surname><given-names>DFB</given-names></name></person-group><article-title>Duffull SB The influence of flip-flop in population pharmacokinetic analyses</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2023</year><volume>12</volume><fpage>285</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1002/psp4.12909</pub-id><pub-id pub-id-type="pmid">36647235</pub-id><pub-id pub-id-type="pmcid">PMC10014047</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kuan IHS, Wright DFB. Duffull SB The influence of flip-flop in population pharmacokinetic analyses. CPT Pharmacometrics Syst Pharmacol. 2023;12:285&#8211;7. 10.1002/psp4.12909.<pub-id pub-id-type="pmid">36647235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12909</pub-id><pub-id pub-id-type="pmcid">PMC10014047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Kotsiopoulou M, Kosmidis K, Tsekouras AA, Macheras P. Is flip-flop kinetics a myth? 33rd Population Approach Group in Europe (PAGE) meeting, Thessaloniki, Greece 4&#8211;6 June 2025.</mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ole-Mapenay</surname><given-names>IM</given-names></name><name name-style="western"><surname>Mitema</surname><given-names>ES</given-names></name></person-group><article-title>Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation</article-title><source>Vet Res Commun</source><year>1995</year><volume>19</volume><issue>5</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/BF01839322</pub-id><pub-id pub-id-type="pmid">8560757</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ole-Mapenay IM, Mitema ES. Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. Vet Res Commun. 1995;19(5):425&#8211;32. 10.1007/BF01839322.<pub-id pub-id-type="pmid">8560757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01839322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toutain</surname><given-names>PL</given-names></name><name name-style="western"><surname>Bousquet-M&#233;lou</surname><given-names>A</given-names></name></person-group><article-title>Plasma terminal half-life</article-title><source>Vet Pharmacol Therap</source><year>2004</year><volume>27</volume><fpage>427</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2885.2004.00600.x</pub-id><pub-id pub-id-type="pmid">15601438</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Toutain PL, Bousquet-M&#233;lou A. Plasma terminal half-life. Vet Pharmacol Therap. 2004;27:427&#8211;39. 10.1111/j.1365-2885.2004.00600.x.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2885.2004.00600.x</pub-id><pub-id pub-id-type="pmid">15601438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmidis</surname><given-names>K</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>On the dilemma of fractal or fractional kinetics in drug release studies: A comparison between Weibull and Mittag-Leffler functions</article-title><source>Int J Pharm</source><year>2018</year><volume>543</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.03.060</pub-id><pub-id pub-id-type="pmid">29614338</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kosmidis K, Macheras P. On the dilemma of fractal or fractional kinetics in drug release studies: A comparison between Weibull and Mittag-Leffler functions. Int J Pharm. 2018;543:269&#8211;73. 10.1016/j.ijpharm.2018.03.060.<pub-id pub-id-type="pmid">29614338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2018.03.060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokoumetzidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>The changing face of the rate concept in biopharmaceutical sciences: From classical to fractal and finally to fractional</article-title><source>Pharm Res</source><year>2011</year><volume>28</volume><fpage>1129</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0370-4</pub-id><pub-id pub-id-type="pmid">21264680</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Dokoumetzidis A, Macheras P. The changing face of the rate concept in biopharmaceutical sciences: From classical to fractal and finally to fractional. Pharm Res. 2011;28:1129&#8211;32. 10.1007/s11095-011-0370-4.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-011-0370-4</pub-id><pub-id pub-id-type="pmid">21264680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Macheras P, Iliadis A. Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches. 2nd ed. Springer; 2016. p. 483. 10.1007/978-3-319-27598-7.</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Piana</surname><given-names>C</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M</given-names></name><name name-style="western"><surname>Burger</surname><given-names>D</given-names></name><name name-style="western"><surname>Della Pasqua</surname><given-names>O</given-names></name><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E</given-names></name></person-group><article-title>Population pharmacokinetics of abacavir in infants, toddlers and children</article-title><source>Br J Clin Pharmacol</source><year>2012</year><volume>75</volume><fpage>1525</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1111/bcp.12024</pub-id><pub-id pub-id-type="pmcid">PMC3690111</pub-id><pub-id pub-id-type="pmid">23126277</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhao W, Piana C, Danhof M, Burger D, Della Pasqua O, Jacqz-Aigrain E. Population pharmacokinetics of abacavir in infants, toddlers and children. Br J Clin Pharmacol. 2012;75:1525&#8211;35. 10.1111/bcp.12024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12024</pub-id><pub-id pub-id-type="pmcid">PMC3690111</pub-id><pub-id pub-id-type="pmid">23126277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veng-Pedersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Gobburu</surname><given-names>JVS</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>MC</given-names></name><name name-style="western"><surname>Straughn</surname><given-names>AB</given-names></name></person-group><article-title>Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach</article-title><source>Biopharm Drug Disp</source><year>2000</year><volume>21</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-081X(200001)21:1&amp;#x0003c;1::AID-BDD207&amp;#x0003e;3.0.CO;2-D</pub-id><pub-id pub-id-type="pmid">11038432</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Veng-Pedersen P, Gobburu JVS, Meyer MC, Straughn AB. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm Drug Disp. 2000;21:1&#8211;6. 10.1002/1099-081X(200001)21:1&lt;1::AID-BDD207&gt;3.0.CO;2-D.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-081x(200001)21:1&lt;1::aid-bdd207&gt;3.0.co;2-d</pub-id><pub-id pub-id-type="pmid">11038432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomeni</surname><given-names>R</given-names></name><name name-style="western"><surname>Bressolle-Gomeni</surname><given-names>F</given-names></name></person-group><article-title>Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods</article-title><source>AAPS J</source><year>2020</year><volume>22</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1208/s12248-020-00445-0</pub-id><pub-id pub-id-type="pmid">32297044</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gomeni R, Bressolle-Gomeni F. Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods. AAPS J. 2020;22:67. 10.1208/s12248-020-00445-0.<pub-id pub-id-type="pmid">32297044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-020-00445-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokoumetzidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system</article-title><source>Int J Pharm</source><year>2006</year><volume>321</volume><issue>1&#8211;2</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.07.011</pub-id><pub-id pub-id-type="pmid">16920290</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm. 2006;321(1&#8211;2):1&#8211;11. 10.1016/j.ijpharm.2006.07.011.<pub-id pub-id-type="pmid">16920290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2006.07.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hens</surname><given-names>B</given-names></name><name name-style="western"><surname>Sinko</surname><given-names>PD</given-names></name><name name-style="western"><surname>Job</surname><given-names>N</given-names></name><name name-style="western"><surname>Dean</surname><given-names>M</given-names></name><name name-style="western"><surname>Al-Gousous</surname><given-names>J</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ziff</surname><given-names>RM</given-names></name><name name-style="western"><surname>Tsume</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bermejo</surname><given-names>M</given-names></name><name name-style="western"><surname>Paix&#227;o</surname><given-names>P</given-names></name><name name-style="western"><surname>Brasseur</surname><given-names>JG</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A</given-names></name><name name-style="western"><surname>Talattof</surname><given-names>A</given-names></name><name name-style="western"><surname>Benninghoff</surname><given-names>G</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P</given-names></name><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H</given-names></name><name name-style="western"><surname>Hasler</surname><given-names>WL</given-names></name><name name-style="western"><surname>Marciani</surname><given-names>L</given-names></name><name name-style="western"><surname>Dickens</surname><given-names>J</given-names></name><name name-style="western"><surname>Shedden</surname><given-names>K</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>GE</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>GL</given-names></name></person-group><article-title>Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' project</article-title><source>Int J Pharm</source><year>2018</year><volume>548</volume><issue>1</issue><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.06.050</pub-id><pub-id pub-id-type="pmid">29944899</pub-id><pub-id pub-id-type="pmcid">PMC8845961</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hens B, Sinko PD, Job N, Dean M, Al-Gousous J, Salehi N, Ziff RM, Tsume Y, Bermejo M, Paix&#227;o P, Brasseur JG, Yu A, Talattof A, Benninghoff G, Langguth P, Lennern&#228;s H, Hasler WL, Marciani L, Dickens J, Shedden K, Sun D, Amidon GE, Amidon GL. Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded &#8220;21st Century BA/BE&#8221; project. Int J Pharm. 2018;548(1):120&#8211;7. 10.1016/j.ijpharm.2018.06.050.<pub-id pub-id-type="pmid">29944899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2018.06.050</pub-id><pub-id pub-id-type="pmcid">PMC8845961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kollipara</surname><given-names>S</given-names></name><name name-style="western"><surname>Boddu</surname><given-names>R</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T</given-names></name><name name-style="western"><surname>Chachad</surname><given-names>S</given-names></name></person-group><article-title>Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development</article-title><source>AAPS PharmSciTech</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1208/s12249-021-02203-7</pub-id><pub-id pub-id-type="pmid">35028797</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kollipara S, Boddu R, Ahmed T, Chachad S. Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development. AAPS PharmSciTech. 2022;23(1):53. 10.1208/s12249-021-02203-7.<pub-id pub-id-type="pmid">35028797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12249-021-02203-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charalabidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Sfouni</surname><given-names>M</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>C</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines</article-title><source>Int J Pharm</source><year>2019</year><volume>20</volume><issue>566</issue><fpage>264</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.05.041</pub-id><pub-id pub-id-type="pmid">31108154</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Charalabidis A, Sfouni M, Bergstr&#246;m C, Macheras P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Int J Pharm. 2019;20(566):264&#8211;81. 10.1016/j.ijpharm.2019.05.041.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2019.05.041</pub-id><pub-id pub-id-type="pmid">31108154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">FDA guidance for industry extended release oral dosage forms: development, evaluation, and application of In Vitro/In Vivo Correlations. Office of training and communications division of communications management. The Drug Information Branch, HFD-210 5600 Fishers Lane Rockville, MD 20857. 1997. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations</ext-link>.</mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toulitsis</surname><given-names>E</given-names></name><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes</article-title><source>Pharm</source><year>2024</year><volume>16</volume><issue>11</issue><fpage>1435</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics16111435</pub-id><pub-id pub-id-type="pmcid">PMC11597828</pub-id><pub-id pub-id-type="pmid">39598557</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Toulitsis E, Tsekouras AA, Macheras P. FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes. Pharm. 2024;16(11):1435. 10.3390/pharmaceutics16111435.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics16111435</pub-id><pub-id pub-id-type="pmcid">PMC11597828</pub-id><pub-id pub-id-type="pmid">39598557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikuta</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Kai</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugano</surname><given-names>K</given-names></name></person-group><article-title>Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets</article-title><source>Eur J Pharm Sci</source><year>2023</year><volume>180</volume><fpage>106326</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2022.106326</pub-id><pub-id pub-id-type="pmid">36347443</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Ikuta S, Nakagawa H, Kai T, Sugano K. Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets. Eur J Pharm Sci. 2023;180:106326. 10.1016/j.ejps.2022.106326.<pub-id pub-id-type="pmid">36347443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2022.106326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M</given-names></name><name name-style="western"><surname>Piao</surname><given-names>H</given-names></name></person-group><article-title>In Vitro-In Vivo Correlation for Solid Dispersion of a Poorly Water-Soluble Drug Efonidipine Hydrochloride</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><issue>5</issue><fpage>160</fpage><pub-id pub-id-type="doi">10.1208/s12249-020-01685-1</pub-id><pub-id pub-id-type="pmid">32476084</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Cheng X, Gao J, Li J, Cheng G, Zou M, Piao H. In Vitro-In Vivo Correlation for Solid Dispersion of a Poorly Water-Soluble Drug Efonidipine Hydrochloride. AAPS PharmSciTech. 2020;21(5):160. 10.1208/s12249-020-01685-1.<pub-id pub-id-type="pmid">32476084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12249-020-01685-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mircioiu</surname><given-names>C</given-names></name><name name-style="western"><surname>Mircioiu</surname><given-names>I</given-names></name><name name-style="western"><surname>Voicu</surname><given-names>V</given-names></name><name name-style="western"><surname>Miron</surname><given-names>D</given-names></name></person-group><article-title>Dissolution-bioequivalence non-correlations</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2005</year><volume>96</volume><issue>3</issue><fpage>262</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2005.pto960324.x</pub-id><pub-id pub-id-type="pmid">15733230</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Mircioiu C, Mircioiu I, Voicu V, Miron D. Dissolution-bioequivalence non-correlations. Basic Clin Pharmacol Toxicol. 2005;96(3):262&#8211;4. 10.1111/j.1742-7843.2005.pto960324.x.<pub-id pub-id-type="pmid">15733230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2005.pto960324.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dokoumetzidis</surname><given-names>A</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure</article-title><source>J Control Release</source><year>2008</year><volume>129</volume><fpage>76</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.04.005</pub-id><pub-id pub-id-type="pmid">18538435</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Dokoumetzidis A, Macheras P. IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure. J Control Release. 2008;129:76&#8211;8. 10.1016/j.jconrel.2008.04.005.<pub-id pub-id-type="pmid">18538435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2008.04.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endrenyi</surname><given-names>L</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name></person-group><article-title>Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence</article-title><source>Int J Clin Pharmacol Ther Toxicol</source><year>1991</year><volume>29</volume><issue>10</issue><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">1748540</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol. 1991;29(10):394&#8211;9.<pub-id pub-id-type="pmid">1748540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>ML</given-names></name></person-group><article-title>An alternative approach for assessment of rate of ab sorption in bioequivalence studies</article-title><source>Pharm Res</source><year>1992</year><volume>9</volume><issue>11</issue><fpage>1380</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1023/A:1015842425553</pub-id><pub-id pub-id-type="pmid">1475222</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Chen ML. An alternative approach for assessment of rate of ab sorption in bioequivalence studies. Pharm Res. 1992;9(11):1380&#8211;5. 10.1023/A:1015842425553.<pub-id pub-id-type="pmid">1475222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1015842425553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>ML</given-names></name><name name-style="western"><surname>Davit</surname><given-names>B</given-names></name><name name-style="western"><surname>Lionberger</surname><given-names>R</given-names></name><name name-style="western"><surname>Wahba</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>LX</given-names></name></person-group><article-title>Using partial area for evaluation of bioavailability and bioequivalence</article-title><source>Pharm Res</source><year>2011</year><volume>28</volume><issue>8</issue><fpage>1939</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0421-x</pub-id><pub-id pub-id-type="pmid">21487930</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Chen ML, Davit B, Lionberger R, Wahba Z, Ahn H-Y, Yu LX. Using partial area for evaluation of bioavailability and bioequivalence. Pharm Res. 2011;28(8):1939&#8211;47. 10.1007/s11095-011-0421-x.<pub-id pub-id-type="pmid">21487930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-011-0421-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name><name name-style="western"><surname>Symillides</surname><given-names>M</given-names></name><name name-style="western"><surname>Reppas</surname><given-names>C</given-names></name></person-group><article-title>An improved intercept method for the assessment of absorption rate in bioequivalence studies</article-title><source>Pharm Res</source><year>1996</year><volume>13</volume><issue>11</issue><fpage>1755</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1023/A:1016421630290</pub-id><pub-id pub-id-type="pmid">8956348</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Macheras P, Symillides M, Reppas C. An improved intercept method for the assessment of absorption rate in bioequivalence studies. Pharm Res. 1996;13(11):1755&#8211;8. 10.1023/A:1016421630290.<pub-id pub-id-type="pmid">8956348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1016421630290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name><name name-style="western"><surname>Symillides</surname><given-names>M</given-names></name><name name-style="western"><surname>Reppas</surname><given-names>C</given-names></name></person-group><article-title>The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies</article-title><source>Pharm Res</source><year>1994</year><volume>11</volume><issue>6</issue><fpage>831</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1023/A:1018921622981</pub-id><pub-id pub-id-type="pmid">7937521</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Macheras P, Symillides M, Reppas C. The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies. Pharm Res. 1994;11(6):831&#8211;4. 10.1023/A:1018921622981.<pub-id pub-id-type="pmid">7937521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1018921622981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panhard</surname><given-names>X</given-names></name><name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></name></person-group><article-title>Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials</article-title><source>Stat Med</source><year>2005</year><volume>24</volume><fpage>1509</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1002/sim.2047</pub-id><pub-id pub-id-type="pmid">15761916</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Panhard X, Mentr&#233; F. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat Med. 2005;24:1509&#8211;24. 10.1002/sim.2047.<pub-id pub-id-type="pmid">15761916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.2047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>A</given-names></name><name name-style="western"><surname>Lavielle</surname><given-names>M</given-names></name><name name-style="western"><surname>Gsteiger</surname><given-names>S</given-names></name><name name-style="western"><surname>Pigeolet</surname><given-names>E</given-names></name><name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></name></person-group><article-title>Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm</article-title><source>Stat Med</source><year>2011</year><volume>30</volume><fpage>2582</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1002/sim.4286</pub-id><pub-id pub-id-type="pmid">21793036</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentr&#233; F. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Stat Med. 2011;30:2582&#8211;600. 10.1002/sim.4286.<pub-id pub-id-type="pmid">21793036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>A</given-names></name><name name-style="western"><surname>Gsteiger</surname><given-names>S</given-names></name><name name-style="western"><surname>Pigeolet</surname><given-names>E</given-names></name><name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></name></person-group><article-title>Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs</article-title><source>Pharm Res</source><year>2010</year><volume>27</volume><fpage>92</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9980-5</pub-id><pub-id pub-id-type="pmid">19876723</pub-id><pub-id pub-id-type="pmcid">PMC2881952</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Dubois A, Gsteiger S, Pigeolet E, Mentr&#233; F. Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs. Pharm Res. 2010;27:92&#8211;104. 10.1007/s11095-009-9980-5.<pub-id pub-id-type="pmid">19876723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-009-9980-5</pub-id><pub-id pub-id-type="pmcid">PMC2881952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>HB</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>AC</given-names></name></person-group><article-title>Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2024</year><volume>13</volume><issue>10</issue><fpage>1734</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1002/psp4.13216</pub-id><pub-id pub-id-type="pmid">39177211</pub-id><pub-id pub-id-type="pmcid">PMC11494825</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Chen X, Nyberg HB, Donnelly M, Zhao L, Fang L, Karlsson MO, Hooker AC. Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points. CPT Pharmacometrics Syst Pharmacol. 2024;13(10):1734&#8211;47. 10.1002/psp4.13216.<pub-id pub-id-type="pmid">39177211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.13216</pub-id><pub-id pub-id-type="pmcid">PMC11494825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts</article-title><source>Pharm Res</source><year>2021</year><volume>38</volume><issue>10</issue><fpage>1635</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03121-w</pub-id><pub-id pub-id-type="pmid">34664204</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Tsekouras AA, Macheras P. Re-examining digoxin bioavailability after half a century: time for changes in the bioavailability concepts. Pharm Res. 2021;38(10):1635&#8211;8. 10.1007/s11095-021-03121-w.<pub-id pub-id-type="pmid">34664204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-021-03121-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolars</surname><given-names>JC</given-names></name><name name-style="western"><surname>Awni</surname><given-names>WM</given-names></name><name name-style="western"><surname>Merion</surname><given-names>RM</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name></person-group><article-title>First-pass metabolism of cyclosporin by the gut</article-title><source>Lancet</source><year>1991</year><volume>338</volume><issue>8781</issue><fpage>1488</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(91)92302-i</pub-id><pub-id pub-id-type="pmid">1683920</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338(8781):1488&#8211;90. 10.1016/0140-6736(91)92302-i.<pub-id pub-id-type="pmid">1683920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0140-6736(91)92302-i</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsekouras</surname><given-names>AA</given-names></name><name name-style="western"><surname>Macheras</surname><given-names>P</given-names></name></person-group><article-title>Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence</article-title><source>Pharm Res</source><year>2024</year><volume>41</volume><issue>7</issue><fpage>1413</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1007/s11095-024-03727-w</pub-id><pub-id pub-id-type="pmid">38898304</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Tsekouras AA, Macheras P. Application of the Finite Absorption Time (F.A.T.) concept in the assessment of bioequivalence. Pharm Res. 2024;41(7):1413&#8211;25. 10.1007/s11095-024-03727-w.<pub-id pub-id-type="pmid">38898304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-024-03727-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Guidelines for biopharmaceutical studies in man. American Association of Pharmaceutical Sciences, Academy of pharmaceutical sciences, Washington D.C., February 1972.</mixed-citation></ref></ref-list></back></article></pmc-articleset>